CN108478703A - A kind of Chinese medicine composition and quality determining method for treating arrhythmia cordis - Google Patents
A kind of Chinese medicine composition and quality determining method for treating arrhythmia cordis Download PDFInfo
- Publication number
- CN108478703A CN108478703A CN201810675116.3A CN201810675116A CN108478703A CN 108478703 A CN108478703 A CN 108478703A CN 201810675116 A CN201810675116 A CN 201810675116A CN 108478703 A CN108478703 A CN 108478703A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- solution
- radix
- ginsenoside
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 282
- 206010003119 arrhythmia Diseases 0.000 title claims abstract description 78
- 230000006793 arrhythmia Effects 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 239000007788 liquid Substances 0.000 claims abstract description 135
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 79
- 238000001914 filtration Methods 0.000 claims abstract description 58
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 51
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 51
- 235000008434 ginseng Nutrition 0.000 claims abstract description 51
- 239000009636 Huang Qi Substances 0.000 claims abstract description 47
- 238000002360 preparation method Methods 0.000 claims abstract description 42
- 239000004615 ingredient Substances 0.000 claims abstract description 40
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 39
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 39
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 39
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 39
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 39
- 210000004165 myocardium Anatomy 0.000 claims abstract description 39
- 239000000843 powder Substances 0.000 claims abstract description 38
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 37
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 37
- 239000000706 filtrate Substances 0.000 claims abstract description 22
- 238000002156 mixing Methods 0.000 claims abstract description 19
- 230000002107 myocardial effect Effects 0.000 claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 15
- 229920001353 Dextrin Polymers 0.000 claims abstract description 12
- 239000004375 Dextrin Substances 0.000 claims abstract description 12
- 235000019425 dextrin Nutrition 0.000 claims abstract description 12
- 238000000605 extraction Methods 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 11
- 239000012141 concentrate Substances 0.000 claims abstract description 10
- 239000006071 cream Substances 0.000 claims abstract description 10
- 239000002552 dosage form Substances 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 10
- 238000010992 reflux Methods 0.000 claims abstract description 10
- 238000001694 spray drying Methods 0.000 claims abstract description 10
- 235000020985 whole grains Nutrition 0.000 claims abstract description 10
- 238000010438 heat treatment Methods 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- 241000208340 Araliaceae Species 0.000 claims abstract 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 117
- 239000000243 solution Substances 0.000 claims description 93
- 238000012360 testing method Methods 0.000 claims description 85
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims description 84
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims description 79
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims description 79
- 229940079593 drug Drugs 0.000 claims description 62
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 57
- 239000013558 reference substance Substances 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 56
- 230000000694 effects Effects 0.000 claims description 47
- 239000000047 product Substances 0.000 claims description 47
- 235000019441 ethanol Nutrition 0.000 claims description 41
- 238000003556 assay Methods 0.000 claims description 36
- 238000004587 chromatography analysis Methods 0.000 claims description 32
- 210000001519 tissue Anatomy 0.000 claims description 30
- 210000002216 heart Anatomy 0.000 claims description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 23
- 230000000747 cardiac effect Effects 0.000 claims description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- -1 decoction Substances 0.000 claims description 18
- 210000004072 lung Anatomy 0.000 claims description 18
- 208000011580 syndromic disease Diseases 0.000 claims description 18
- 239000012085 test solution Substances 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 17
- 238000001514 detection method Methods 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 16
- 238000002474 experimental method Methods 0.000 claims description 16
- 238000011084 recovery Methods 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 15
- 235000009508 confectionery Nutrition 0.000 claims description 15
- 239000000796 flavoring agent Substances 0.000 claims description 15
- 235000019634 flavors Nutrition 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 13
- 238000005259 measurement Methods 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- 230000007812 deficiency Effects 0.000 claims description 12
- 238000011161 development Methods 0.000 claims description 12
- 210000002784 stomach Anatomy 0.000 claims description 12
- 210000003462 vein Anatomy 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 11
- 230000017531 blood circulation Effects 0.000 claims description 10
- 239000012071 phase Substances 0.000 claims description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims description 9
- 239000001116 FEMA 4028 Substances 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 9
- 229910052782 aluminium Inorganic materials 0.000 claims description 9
- 239000004411 aluminium Substances 0.000 claims description 9
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 9
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 9
- 229960004853 betadex Drugs 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000013642 negative control Substances 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000006187 pill Substances 0.000 claims description 9
- 238000004064 recycling Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 210000000952 spleen Anatomy 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 239000008945 zhigancao decoction Substances 0.000 claims description 9
- 238000007689 inspection Methods 0.000 claims description 8
- 238000002137 ultrasound extraction Methods 0.000 claims description 8
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 7
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 6
- 239000012895 dilution Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000009858 dingxin Substances 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 206010013975 Dyspnoeas Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 210000001367 artery Anatomy 0.000 claims description 4
- 238000011088 calibration curve Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 239000002075 main ingredient Substances 0.000 claims description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 4
- 238000011160 research Methods 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 claims description 3
- 206010011224 Cough Diseases 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 102000001554 Hemoglobins Human genes 0.000 claims description 3
- 108010054147 Hemoglobins Proteins 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 208000004880 Polyuria Diseases 0.000 claims description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 3
- 206010038743 Restlessness Diseases 0.000 claims description 3
- 208000005392 Spasm Diseases 0.000 claims description 3
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims description 3
- 208000037386 Typhoid Diseases 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 230000003712 anti-aging effect Effects 0.000 claims description 3
- 230000002929 anti-fatigue Effects 0.000 claims description 3
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 3
- 230000009286 beneficial effect Effects 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- GLMWWMZIEZJGMT-UHFFFAOYSA-N chloroform;formic acid;propan-2-one Chemical compound OC=O.CC(C)=O.ClC(Cl)Cl GLMWWMZIEZJGMT-UHFFFAOYSA-N 0.000 claims description 3
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 230000035619 diuresis Effects 0.000 claims description 3
- 239000012154 double-distilled water Substances 0.000 claims description 3
- 230000002349 favourable effect Effects 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 claims description 3
- 230000036284 oxygen consumption Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 3
- 229960003371 protocatechualdehyde Drugs 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 3
- 238000010926 purge Methods 0.000 claims description 3
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 238000013112 stability test Methods 0.000 claims description 3
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims description 3
- 235000021286 stilbenes Nutrition 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 201000008297 typhoid fever Diseases 0.000 claims description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims description 2
- 150000002338 glycosides Chemical class 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 238000012372 quality testing Methods 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 150000001343 alkyl silanes Chemical group 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 238000004809 thin layer chromatography Methods 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
- 230000005405 multipole Effects 0.000 abstract description 3
- 210000000170 cell membrane Anatomy 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 92
- 206010003658 Atrial Fibrillation Diseases 0.000 description 45
- 230000014509 gene expression Effects 0.000 description 44
- 239000000523 sample Substances 0.000 description 37
- 240000005373 Panax quinquefolius Species 0.000 description 31
- 108020004999 messenger RNA Proteins 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 29
- 238000003304 gavage Methods 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 19
- 230000008859 change Effects 0.000 description 18
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 17
- 101710177922 Gap junction alpha-5 protein Proteins 0.000 description 13
- 229960001722 verapamil Drugs 0.000 description 13
- 102100030540 Gap junction alpha-5 protein Human genes 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 12
- 230000034994 death Effects 0.000 description 12
- 235000008216 herbs Nutrition 0.000 description 12
- 102000020233 phosphotransferase Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 11
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 11
- 230000002861 ventricular Effects 0.000 description 11
- 102000007469 Actins Human genes 0.000 description 10
- 108010085238 Actins Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 10
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 230000007774 longterm Effects 0.000 description 10
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 9
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 230000003387 muscular Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 108091006146 Channels Proteins 0.000 description 8
- 241000721047 Danaus plexippus Species 0.000 description 8
- 230000001746 atrial effect Effects 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- YXAGIVZEXFSYNE-UHFFFAOYSA-M C(C)(=O)OCC[N+](C)(C)C.[Cl-].[Ca] Chemical compound C(C)(=O)OCC[N+](C)(C)C.[Cl-].[Ca] YXAGIVZEXFSYNE-UHFFFAOYSA-M 0.000 description 7
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 7
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 5
- 108010052164 Sodium Channels Proteins 0.000 description 5
- 102000018674 Sodium Channels Human genes 0.000 description 5
- 208000010513 Stupor Diseases 0.000 description 5
- 239000003416 antiarrhythmic agent Substances 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 206010002660 Anoxia Diseases 0.000 description 4
- 241000976983 Anoxia Species 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 230000007953 anoxia Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- 239000003390 Chinese drug Substances 0.000 description 3
- XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 208000032845 Atrial Remodeling Diseases 0.000 description 2
- 201000006306 Cor pulmonale Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 2
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 2
- 239000002021 butanolic extract Substances 0.000 description 2
- 230000001964 calcium overload Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 210000001013 sinoatrial node Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 2
- 229910001948 sodium oxide Inorganic materials 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001026885 Homo sapiens Serine/threonine-protein kinase D3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101000990901 Rattus norvegicus Matrix metalloproteinase-9 Proteins 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 102100037311 Serine/threonine-protein kinase D3 Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 229940110331 bextra Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 229960004895 bretylium tosylate Drugs 0.000 description 1
- KVWNWTZZBKCOPM-UHFFFAOYSA-M bretylium tosylate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC[N+](C)(C)CC1=CC=CC=C1Br KVWNWTZZBKCOPM-UHFFFAOYSA-M 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 229960001142 encainide Drugs 0.000 description 1
- PJWPNDMDCLXCOM-UHFFFAOYSA-N encainide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1N(C)CCCC1 PJWPNDMDCLXCOM-UHFFFAOYSA-N 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 230000001121 heart beat frequency Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008700 sympathetic activation Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- DNYWZCXLKNTFFI-UHFFFAOYSA-N uranium Chemical compound [U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U] DNYWZCXLKNTFFI-UHFFFAOYSA-N 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A kind of Chinese medicine composition and quality determining method for treating arrhythmia cordis, including Chinese medicine major ingredient and pharmaceutic adjuvant, the Chinese medicine major ingredient are made of following ingredients weight parts proportioning Chinese medicine:Honey-fried licorice root, Radix Rehmanniae, ginseng, Radix Astragali, Radix Ophiopogonis, Radix Salviae Miltiorrhizae, safflower, spina date seed.Preparation method includes the following steps:Honey-fried licorice root, Radix Rehmanniae, ginseng, Radix Astragali are taken in prescription ratio, twice, filtering, filtrate merges heating and refluxing extraction;Radix Ophiopogonis, Radix Salviae Miltiorrhizae, safflower, spina date seed are taken in prescription ratio, the gained dregs of a decoction are added, obtains liquid, distillate is collected, carries out coarse filtration and refined filtration with plate and frame filter press, concentrate spray drying process prepares extract powder;Dextrin mixing is added in cream powder, is pelletized with ethanol wet, wet granular boiled bed drying, whole grain, both obtains finished dosage form.The invention can adjust the compliance of patient's cardiac muscle, reduce intra-atrial reentry, stablize myocardial cell membrane, improve the multipole conducting system function of cardiac muscle, improve the quality of life of patient, will be widely used in technical field of Chinese medicine.
Description
Technical field
The present invention relates in technical field of Chinese medicine a kind of Chinese medicine composition that treating arrhythmia cordis and quality testing side
Method.
Background technology
Currently, arrhythmia cordis is since sinoatrial node excitement exception or excitement result from other than sinoatrial node, exciting conduction is slow
Slowly, block or conducted through abnormal passage, i.e., the origin of cardiomotility and (or) conductive impairment cause heartbeat frequency and
(or) allorhythmia.Arrhythmia cordis is one group of disease important in angiocardiopathy.It can individually fall ill, also can be with other painstaking effort
Pipe disease occurs together.Whether its prognosis and the cause of disease of arrhythmia cordis inducement, evolving trend, cause serious hemodynamic obstacle related, can
It breaks out and causes to die suddenly, it is also sustainable to involve heart and cause its failure.Premature beat is the most common type arrhythmia cordis.Premature beat is again
Referred to as Premature contracfion.It refer to heartbeat caused by the too early impulsion that ectopic pacemaker is sent out.Sinus property or atopy can be happened at
On the basis of (such as auricular fibrillation) rhythm of the heart.It can be accidental or takes place frequently, it can be irregularly or regular at each or per several normal
Occur after beating, forms bigeminy or connection rule property Premature contracfion.It can be divided into sinus property, Fang Xing, atrioventricular junction by origin position
With four kinds of room property.Wherein most common with ventricular premature beat, followed by room, knot property are more rare.Arrhythmia cordis is in angiocardiopathy
One group of important disease.It can individually fall ill, and can also occur together with other cardiovascular diseases.The cause of disease of its prognosis and arrhythmia cordis lures
Whether cause, evolving trend cause serious hemodynamic obstacle related, can break out and cause to die suddenly, also sustainable to involve heart
And cause its failure.
The classification of antiarrhythmic drug has been continued to use nearly 30 years.Drug is divided into according to pharmaceutically-active electro physiology feature
Four classes.I class blocks the sodium channel of cardiac muscle and conducting system of heart, has membrane stabilizing action, reduces by 0 phase depolarization of action potential and rises
Rate and amplitude slow down conduction of velocity, over reach potential duration (APD) and event related potential (ERP).To resting membrane electric potential
Without influence.According to drug to the difference of sodium channel retardation, it is divided into as three subclass, i.e. I a, Ib, I c.
(1) I a class appropriateness block sodium channels bring back to life time constant 1-10s, and the most notable to extend ERP, drug includes Kui
Buddhist nun's fourth, procainamide, disopyramide etc..
(2) the I slight block sodium channels of b classes bring back to life time constant<1s reduces self-disciplining, and drug includes lidocaine, benzene
Appropriate English sodium, mexiletine etc..
(3) the I apparent block sodium channels of c classes bring back to life time constant>It is most strong to slow down conductive effect by 10s.Drug includes
Propafenone, Encainide, Flecainide etc..
II class Bextra inhibits pacemaker current, sodium current and L-type calcium current caused by sympathetic activation to increase
Add, show as slowing down four phase diastole depolarization rates and reducing self-disciplining, reduces by 0 phase climbing speed of action potential and slow down conduction
Property.Drug includes Propranolol, atenolol, metoprolol etc..
III class over reach potential duration medicine, inhibits a variety of potassium currents, drug include amiodarone, Sotalol, bretylium tosylate,
According to cloth for sharp and how non-for profit etc..
IV class calcium channel blocker, including Verapamil and diltiazem etc..
It is noted that grasping the indication of antiarrhythmic drug in clinic, and not all arrhythmia cordis is both needed to apply the anti-heart
Arrhythmic agents are restrained, only directly result in apparent symptom or haemodynamics obstacle or with the malignant cardiac rhythm for causing fatal risk
It just needs to be treated for arrhythmia cordis when not normal.Antiarrhymic has inevitably bad anti-in clinical application
It answers.Such as:Nausea,vomiting,diarrhea, abdominal pain, cacesthesia, clouding of consciousness, delirium, stupor, aggravation asthma and chronic obstructive pulmonary
The adverse reactions such as disease, intermittent claudication, Raynaud's phenomenon, mental depression, bradycardia.Therefore, development is a kind for the treatment of the heart
It restrains not normal Chinese medicine composition and quality determining method is always new issue anxious to be resolved.
Invention content
The purpose of the present invention is to provide a kind of Chinese medicine composition and quality determining method for treating arrhythmia cordis, the inventions
Palatelet-selectin in rat plasma can be reduced, thromboxane B2 (TXB2), matrix metalloproteinase 9 in atrial fibrillation rat blood serum can be reduced
(MMP-9) content lowers plasminogen activator inhibitor (PAI-I) level in rat blood serum, to mitigate the breaking-out of atrial fibrillation,
The Ca of cardiac muscular tissue can be lowered2+ATP enzyme genetic transcription reaches calcium overload when improving atrial fibrillation, delays the hair of atrial electrical remodeling
It is raw, the effect of " AF causes AF " is prevented, Cx40 gene expression doses can be substantially reduced, the multiple generation turned back in atrium can be reduced,
The expression for adjusting kinases 2 (ERK2) mRNA outside atrial fibrillation rat heart muscle histocyte can be raised, atrial fibrillation rat can be lowered
Cardiac muscular tissue's L-type calcium channel mRNA expression is horizontal, and is effectively improved the variation of atrial fibrillation myocardial ultrastructure.
The object of the present invention is achieved like this:A kind of Chinese medicine composition for treating arrhythmia cordis, including Chinese medicine major ingredient and
Pharmaceutic adjuvant, the Chinese medicine major ingredient are made of following ingredients weight parts proportioning Chinese medicine:Honey-fried licorice root 25-40g, Radix Rehmanniae 25-
30g, ginseng 20-25g, Radix Astragali 25-40g, Radix Ophiopogonis 25-40g, Radix Salviae Miltiorrhizae 35-40g, safflower 20-25g, spina date seed 20-40g;
The Chinese medicine major ingredient is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 30g, Radix Rehmanniae 25g, people
Join 20g, Radix Astragali 30g, Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 20g;
The Chinese medicine major ingredient is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 30g, Radix Rehmanniae 25g, people
Join 25g, Radix Astragali 25g, Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 25g;
The Chinese medicine major ingredient is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 25g, Radix Rehmanniae 30g, people
Join 20g, Radix Astragali 35g, Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 20g;
The Chinese medicine major ingredient is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 25g, Radix Rehmanniae 25g, people
Join 20g, Radix Astragali 30g, Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 40g, safflower 20g, spina date seed 25g;
The Chinese medicine major ingredient is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 30g, Radix Rehmanniae 25g, people
Join 20g, Radix Astragali 30g, Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 35g, safflower 25g, spina date seed 25g;
The Chinese medicine major ingredient is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 40g, Radix Rehmanniae 25g, people
Join 25g, Radix Astragali 30g, Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 25g;
The Chinese medicine major ingredient is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 25g, Radix Rehmanniae 25g, people
Join 20g, Radix Astragali 30g, Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 35g, safflower 25g, spina date seed 40g;
The Chinese medicine major ingredient is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 35g, Radix Rehmanniae 30g, people
Join 25g, Radix Astragali 25g, Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 30g;
The Chinese medicine major ingredient is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 35g, Radix Rehmanniae 30g, people
Join 20g, Radix Astragali 25g, Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 40g, safflower 20g, spina date seed 40g;
The pharmaceutic adjuvant is one or more of in dextrin, starch, lactose;
A kind of preparation method of Chinese medicine composition for treating arrhythmia cordis includes the following steps:
(1) honey-fried licorice root, Radix Rehmanniae, ginseng, Radix Astragali are taken in prescription ratio, 70% ethyl alcohol measured with 10 times is heated to reflux and carries
It takes twice, 2 hours every time, filters, filtrate merges, and recycling ethyl alcohol obtains liquid I;
(2) Radix Ophiopogonis, Radix Salviae Miltiorrhizae, safflower, spina date seed are taken in prescription ratio, impregnated 30 minutes, the gained dregs of a decoction in step (1) are added
Entering, common decocting 2 times, for the first time 12 times of water, decocts 2 hours, filtration obtains liquid II, and second of 8 times of water decocts 1.5 hours,
Filtration, obtains liquid III, collects distillate twice, obtain liquid IV;
(3) liquid I, II, III, IV is merged, mixing carries out coarse filtration and refined filtration, refined filtration liquid triple effect with plate and frame filter press
It is 1.15 that energy-saving concentrator, which is concentrated into relative density, temperature 60 C;Concentrate spray drying process, 6000 milliliters of feed speed/
Minute, 6000 revs/min of centrifugal speed, 120 DEG C of inlet air temperature prepares extract powder;20% dextrin mixing is added in cream powder, uses
80% ethanol wet is pelletized, wet granular boiled bed drying, 75 DEG C of wind-warm syndrome;Beta-cyclo dextrin included compound powder, whole grain is added;It examines and divides
Loaded in aluminium plastic membrane bag, 3 grams are often wrapped, both obtains finished dosage form;
Preparation in the step (3) is pill, capsule, decoction, powder, electuary, particle or oral solution;
A kind of quality determining method of Chinese medicine composition for treating arrhythmia cordis is as follows:
One, instrument and reagent
LC-10P liquid phase pump LC-10UV UV detector, big Liaanjiang county Shen separation science Technology Co., Ltd. production;Chromatographic column
1(Hypersil):Dalian Yi Lite Co., Ltds provide;5 μ, 4.6mm × 200mm;Chromatographic column 2 (Spherigel):Big Liaanjiang county
Shen separation science Co., Ltd provides;5 μ, 4.6mm × 200mm;Agents useful for same acetonitrile is chromatographically pure, and Shandong king's Yu industry is limited
Company Yucheng chemical plant;Water is double distilled water, and other reagents are that analysis is pure;Ginsenoside Rg1's reference substance, Chinese drug biology system
Product examine is fixed to be provided, and assay is used, lot number 0703-9812;
Two, method and result
1, thin layer differentiates
(1) thin layer of Radix Salviae Miltiorrhizae differentiates
This product content 2g is taken, water 50ml, ultrasonic extraction 30 minutes is added to let cool, centrifuges, supernatant is taken, with dilute hydrochloric acid tune
Section pH value is 1-2, is extracted 2 times, each 20ml with ethyl acetate, merges ethyl acetate liquid, is evaporated, it is molten that residue adds methanol 1ml to make
Solution, as test solution;Protocatechualdehyde reference substance separately is taken, adds methanol that solution of every 1ml containing 1mg is made, product are molten as a contrast
Liquid;It is tested according to thin-layered chromatography, with reference to Chinese Pharmacopoeia one annex VIB of version in 2000, draws 5 μ l of reference substance solution, test sample
Solution 10-20 μ l, put on the silica gel g thin-layer plate in same using 0.4% sodium carboxymethylcellulose as binder, respectively with chloroform-
Acetone-formic acid is solvent, chloroform:Acetone:The ratio of formic acid is 8:1:1, it is unfolded, takes out, dry, sprays with 5% ferric trichloride
Ethanol solution, it is clear that hot wind is blown to spot development, sets and is inspected under daylight;In test sample chromatography, corresponding with reference substance chromatography
On position, the spot of same color is shown;
(2) thin layer of Radix Astragali differentiates
This product content 3g is taken, methanol 30ml is added, is ultrasonically treated 30 minutes, lets cool, is filtered, filtrate is evaporated, and residue adds water
20ml makes dissolving, is transferred in separatory funnel, adds water saturated n-butanol shaking extraction 2 times, is followed successively by 30ml, 20ml, merges
N-butanol extracting liquid is washed 2 times, each 20ml with 1% sodium hydroxide solution, discards lye, then the washing being saturated with n-butanol
It washs 2 times, each 15ml, discards aqueous, n-butanol liquid is evaporated, and residue adds methanol 1-2ml to make dissolving, as test solution;Separately
Astragaloside IV reference substance is taken, adds methanol that solution of every 1ml containing 0.5mg is made, as a contrast product solution;It is tried according to thin-layered chromatography
It tests, with reference to one VI B of annex of China's coastal port, draws each 5 μ l of above two solution, put respectively thin in same silica G
On laminate, using 10 DEG C of overnight lower layer's solution arranged below of chlorofonn-ethylacetate-methanol-water as solvent, chloroform:Acetic acid second
Ester:Methanol:The ratio of water is 15: 40: 22: 10, is unfolded, and takes out, dries, and spray is heated with 10% ethanol solution of sulfuric acid, at 105 DEG C
It is clear to spot development;In test sample chromatography, on position corresponding with reference substance chromatography, the spot of same color is shown;
(3) thin layer of spina date seed differentiates
This product content 4g is taken, water 50ml, ultrasonic extraction 30 minutes is added to let cool, centrifuges, takes supernatant, use water saturated
N-butanol extracts three times, and each 25ml merges n-butanol liquid, is extracted 2 times, each 50ml with ammonia solution, discards ammonia solution, positive fourth
Alcohol liquid is extracted 2 times, each 30ml with distilled water, discards aqueous solution, and n-butanol liquid is evaporated, and residue adds methanol 1ml to make dissolving, as
Test solution;Saponin A reference substance separately is taken, adds methanol that solution of every 1ml containing 1mg is made, as a contrast product solution.According to
Thin-layered chromatography is tested, and with reference to Chinese Pharmacopoeia version one in 2000, annex VI B draw each 5-10 μ l of above two solution, point
Other point is on same silica gel g thin-layer plate, using 10 DEG C of lower layer's solution arranged below of chloroform-methanol-water as solvent, chloroform:First
Alcohol:The ratio of water is 65:35:10, it is unfolded, takes out, dry, sprays with 1% vanillic aldehyde concentrated sulfuric acid solution, hot wind is blown to spot development
Clearly, it sets and is inspected under daylight;In test sample chromatography, on the corresponding position of product chromatography, the spot of same color 1 is shown;
2, assay
(1) chromatographic condition:
Chromatographic column 1 (Hypersil):5 μ, 4.6mm × 200mm;Chromatographic column 2 (Spherigel):5 μ, 4.6mm × 200mm;
It is filler with octadecylsilane chemically bonded silica;- 0.05% phosphoric acid of acetonitrile is mobile phase;Acetonitrile:The ratio of 0.05% phosphoric acid
It is 20:80, Detection wavelength 203nm;
(2) preparation of reference substance solution:
Precision weighs ginsenoside Rg1 reference substance 10.78mg, is placed in 10ml volumetric flasks, methanol is added to make it dissolve in right amount
And it is diluted to scale, product solution as a contrast after shaking up;Precision draws above-mentioned reference substance solution 2.5ml, is placed in 5ml volumetric flasks
In, add methanol dilution to scale, product dilute solution as a contrast after shaking up, a concentration of 0.539mg/ml of dilute solution;
(3) preparation of test solution:
The a small amount of content of this product is taken, it is finely ground, take 2g, it is accurately weighed and water-saturated n-butanol 50ml is added, it is weighed heavy again
Amount, ultrasonic extraction 30 minutes are stood overnight, and twice ultrasonic extracts 30 minutes, and weighed weight supplies less loss with water-saturated n-butanol
Weight, filtration discards primary filtrate, collects subsequent filtrate;Precision draws subsequent filtrate 25ml, sets in separatory funnel, with 0.5% hydrogen
Aqueous solution of sodium oxide washs 2 times, each 10ml, merges butanol solution, and the water 15ml being saturated with n-butanol is washed 1 time, is discarded
Water lotion, butanol solution water bath method;Residue adds methanol to make to be dissolved in 25ml measuring bottles, adds methanol dilution to scale, shakes up,
It is filtered to obtain the final product with miillpore filter, empty a diameter of 0.45 μm of the net of miillpore filter;
(4) selection of Detection wavelength:
Ginsenoside Rg1's reference substance solution 50 μ l, solution concentration 1.078mg/ml are taken, adds methanol about 5ml, uses Shimadzu
UV-260 is scanned in 400-200nm wave-length coverages, and UV absorption figure is shown in Fig. 1, can be seen that ginseng from UV absorption Fig. 1
Saponin(e Rg1 has absorption peak in 203nm;Therefore select 203nm for ginsenoside Rg1's assay wavelength;
(5) ginsenoside Rg1's reference substance linear relationship is investigated:
Accurate 2 μ l of ginsenoside Rg1's reference substance dilute solution, 4 μ l, 6 μ l, 8 μ l and 10 μ l, the solution concentration drawn is respectively
1.078mg/ml is injected separately into liquid chromatograph, measures ginsenoside Rg1's chromatographic peak peak area, sample size and peak area
Relationship is shown in Table 1;
1 ginsenoside Rg1's reference substance sample size of table and peak area relationship
Sample size μ g | 2.156 | 4.312 | 6.468 | 8.624 | 10.078 |
Peak area | 10202387 | 22357595 | 32868559 | 45702492 | 56099805 |
Calibration curve equation is Y=9.163 × 10-8X+1.074×10-2R=0.9997;
Sample introduction is ranging from:2.156 μ of μ g~10.078 g;
(6) precision test:
20,090801 sample of lot number is taken, it is finely ground, 2g is taken, it is accurately weighed, by test liquid preparation side under " assay " item
Method is tested, and precision draws 5 μ l of test liquid, is amounted to 5 parts, is injected separately into liquid chromatograph, and ginsenoside Rg1's peak area point is measured
Not Wei 20254816,20722368,19968224,20929208,20274486, relative standard deviation 1.90%;
(7) blank test:
Recipe quantity medicinal material is taken, ginseng is removed, negative controls are made by preparation process, then press and tried under " assay " item
It tests, prepares the negative controls solution for lacking ginseng crude drug;By negative controls solution, test solution and each 5 μ of reference substance solution
L is injected separately into liquid chromatograph, and measurement result shows that negative fluid has no phase at ginsenoside Rg1's chromatographic peak retention time
Impurity peaks are answered to interfere;
(8) stability test:
20,090801 sample of lot number is taken, it is finely ground, 2g is taken, it is accurately weighed, by test liquid preparation side under " assay " item
Method is tested, and when test liquid is placed 0,4,8 and 12 hour, draws test liquid and each 5 μ of ginsenoside Rg1's reference substance solution
L is injected separately into liquid chromatograph, and it is respectively 20254816,20557692,20527968,20977204 to measure peak area, phase
It is 1.45% to standard deviation;From test result it is found that test liquid is placed 12 hours, Determination of Content of Ginsenoside Rg_1 is basicly stable.From
The above results are it is found that this assay method, test solution precision are good;
(9) reappearance test:
20,090801 sample of lot number is taken, it is finely ground, 2g is taken, it is accurately weighed, by test liquid preparation side under " assay " item
Method is tested, Determination of Content of Ginsenoside Rg_1 in determination sample, and result is:8.86,8.98,9.08,9.02,8.80mg/, averagely contain
Amount is 8.94mg/, relative standard deviation 1.29%;From test result it is found that Determination of Content of Ginsenoside Rg_1 measures reproducibility examination
It tests and meets regulation;
(10) sample recovery rate is tested:
20,090801 sample of lot number is taken, it is finely ground, 1g is taken, it is accurately weighed, by test liquid preparation side under " assay " item
Method is tested, and amounts to 5 parts, and difference is accurate to be added ginsenoside Rg1 reference substance 17mg, by being tested under " assay " item, measures and adds
Determination of Content of Ginsenoside Rg_1 in standard specimen product calculates, obtains the rate of recovery of this content assaying method ginsenoside Rg1;Its test result
It is shown in Table 2;
2 Determination of Content of Ginsenoside Rg_1 of table measures recovery test result
From above-mentioned recovery test result it is found that this method rate of recovery is good;
(11) Determination of Content of Ginsenoside Rg_1 measures in sample:
Each 20 of the sample of different lot numbers is taken, it is finely ground, 2g is taken, it is accurately weighed, by method test under " assay " item, survey
Determine Determination of Content of Ginsenoside Rg_1, calculates, the result is shown in tables 3;
Determination of Content of Ginsenoside Rg_1 measurement result in 3 sample of table amounts to 10 batches
Determination of Content of Ginsenoside Rg_1 in sample is can be seen that in 5.61mg/ -9.88mg/ grains from above-mentioned test result
Between, therefore ginseng will be defined as in finished product must not be less than 5.0mg in terms of ginsenoside Rg1;
Three, conclusion
1, pharmacodynamic action
A kind of Chinese medicine composition that treating arrhythmia cordis is formed by zhigancao decoction addition or subtraction of changes;Zhigancao decoction derives from Zhang Zhong
Scape《The Treatise on Fevrile Diseases》, " typhoid fever, intermittent pulse severe palpilation, zhigancao decoction master it " primary efficacy be benefiting qi and nourishing yin, activate yang multiple arteries and veins;It is a kind of
The Chinese medicine composition for treating arrhythmia cordis is by eight taste such as Radix Rehmanniae, ginseng, Radix Astragali, Radix Ophiopogonis, Radix Glycyrrhizae, spina date seed, Radix Salviae Miltiorrhizae, safflower
Medicine forms;Research through modern pharmacology, a kind of Chinese medicine composition that treating arrhythmia cordis have good antiarrhythmic work
With;Honey-fried licorice root:Effect is invigorating middle warmer and replenishing QI, and relieving spasm to stop pain moistens the lung and relieve the cough, purging intense heat and detonicating, mediation property of medicine;It is sweet in flavor mild-natured, returns spleen,
Stomach, the heart, lung channel;Gas and property are slow, and can rise can drop;Modern medicine study, honey-fried licorice root have apparent antiarrhythmic effect, sugared skin
Matter hormone-like effect, anti-oxidant and anti-aging effects;Radix Rehmanniae:Effect is nourishing Yin and clearing heat, and cool blood is enriched blood.It is sweet in flavor, bitter, it is slightly cold, returns
The heart, liver, stomach, the thick drop of matter are let out;Myocardial blood flow amount, reducing heart rate can be increased, and there is certain antihypertensive effect;It is yellow
Stilbene:Function be it is raw with can invigorating qi for consolidating superficies, inducing diuresis for removing edema;Toast with can tonifying middle-Jiao and Qi, control all laboured breathing syndrome of blood deficiency;Nature and flavor, it is sweet, it is micro-
Temperature enters lung, the spleen channel;It can significantly improve heart discharge, cardiac index, the often amount of fighting and index of often fighting;Ginseng:It can reinforce vital energy,
Calm the nerves, internal lesion caused by overexertion it is deficient, deficiency of food, the card of all qi and blood sperm deficiencies such as burnout;Nature and flavor:It is sweet, slight bitter, temperature;Enter spleen, lung channel;Energy
Enhance myocardial contractive power, increase cardiac output, there is cardiac effect;Increase coronary blood flow, reducing heart rate, resist myocardial ischemia work
With anti anoxia and protection cardiac muscle reduce myocardial oxygen consumption, reduce affinity of the hemoglobin to oxygen, more to tissue release
Oxygen;Radix Ophiopogonis:Effect is nourishing Yin and moistening lung, beneficial stomach production of sperm, relieving restlessness that clears away heart-fire;Nature and flavor are sweet, slight bitter, cold nature, return lung, stomach, the heart channel of Hang-Shaoyin;It improves
Myocardial contractive power and cardiac pumping function improve tolerance of the mouse ischemic myocardium to bottom oxygen, improve cardiac muscle cell's nutrition, blood flow
Amount, anti-oxidant, antifatigue effect promote liquid immune;Thus a kind of Chinese medicine composition for treating arrhythmia cordis is clinically
Play the role for the treatment of arrhythmia cordis well;
2, detection method result
This test result establishes a kind of quality determining method of Chinese medicine composition that treating arrhythmia cordis, and ginseng is one kind
The main ingredient of the Chinese medicine composition of arrhythmia cordis, ginsenoside Rg1 containing active ingredient are treated, and content is higher, as in said preparation
Main component, content directly influences therapeutic effect, therefore uses high performance liquid chromatography, using it as the finger of assay
Ingredient is marked, can reflect the quality of said preparation, a kind of Chinese medicine composition that treating arrhythmia cordis is made with the content of ginsenoside Rg1
It is reasonable for the index of quality control;Simultaneously using according to thin-layered chromatography, to spina date seed in preparation, Radix Salviae Miltiorrhizae, Radix Astragali is determined
Property differentiate, as a result on position corresponding with reference substance chromatography, show same color spot, method favorable reproducibility;The quality is examined
The foundation of survey method is for reducing preparation differences between batches, ensureing the quality of the pharmaceutical preparations, ensure that clinical efficacy is of great significance, and method
Easy to operate, accurate, reproducible, specificity is strong, can be used for controlling the quality of Dingxin capsule.
The present invention is characterized by its Chinese medicine composition proportioning, preparation method and quality determining method.Its principle is:It visits
Study carefully a kind of quality determining method of Chinese medicine composition that treating arrhythmia cordis, a kind of Chinese medicine composition that treating arrhythmia cordis is to face
Empirical formula of the bed for treating arrhythmia cordis more than two decades.By in eight taste such as Radix Rehmanniae, ginseng, Radix Astragali, Radix Ophiopogonis, Radix Glycyrrhizae, spina date seed
The effect of medicine compatibility forms, and there is invigorating heart gas to help heart-yang, grows the heart-yin nourishing heart blood, and heart arteries and veins is answered in promoting blood circulation.Preferably to control in it
In quality and clinical efficacy, we are with a kind of active ingredient ginseng soap of main ingredient ginseng in Chinese medicine composition for treating arrhythmia cordis
Glycosides Rg1 is index, using the content of Radix Ginseng by HPLC saponin(e Rg1, while to Radix Salviae Miltiorrhizae in preparation, Radix Astragali, acid
Three taste medicine of jujube kernel carries out thin-layer qualitative discriminating, and foundation is provided for the complete quality standards in Chinese drugs of determination.
Chinese medicine has significant advantage to the correction of arrhythmia cordis, and treatment arrhythmia cordis is significant in efficacy, before having wide development
Scape.Without serious adverse reaction." monarch " combination principle of Chinese medicine:《Sheng Nong's herbal classic》:" 120 kinds of medicine-feeding is monarch,
It is main to support life;120 kinds of Chinese medicine is minister, and master nourishs one's nature;Putting in poison 120 kinds makes for assistant, cures mainly disease;Medication must close the monarch and his subjects' assistant
Make." monarch drug in a prescription:It is the drug for main disease or main symptom its primary treatment effect.Ministerial drug:It is that auxiliary monarch drug in a prescription reinforces the main disease for the treatment of, master
The drug of card.Adjutant:It is the therapeutic effect for reinforcing monarch, ministerial drug, supervises its toxicity and high strong property, or prevent seriously ill heresy
Very, the drug of expulsion of yin-yang.Make medicine:Drug with tying-in and reconciliation effect in the side of being.Among one side, monarch drug in a prescription must be indispensable,
And minister, help, make three medicines then can take the circumstances into consideration configure or delete.Monarch minister, helps, makes --- and it is the group that tcm prescription medication must comply with
Knit principle, be it is dialectical, legislation on the basis of, according to the needs of the state of an illness, the principle that comedicine is combined.It is every according to performance
Herbal medicine is different.
According to clinical practice and theoretical research, from quasi- fixed core square, medicine group becomes:Honey-fried licorice root, Radix Rehmanniae, ginseng, Radix Astragali,
Radix Ophiopogonis, Radix Salviae Miltiorrhizae, safflower, spina date seed.In the application, it is different according to the different compatibilities of illness.Premature beat point functionality and device matter
Property, concerted application of drugs is different, and functional premature beat spina date seed dosage is big, organic premature beat ginseng, Radix Astragali, Radix Salviae Miltiorrhizae dosage
Greatly.By multiple zoopery and clinical test, nine kinds of proportioning dosage are proposed according to Chinese prescription principle, wherein zoopery
Seven kinds of Chinese prescriptions, two kinds of Chinese prescriptions of clinical test are in varied situations applied to premature beat, the treatment of atrial fibrillation.Chinese medicine
What is do not passed secret is in dosage ", it is seen that drug dose is an important factor for influencing compound effect, is clinical practice of Chinese medicine experience product
Tired crystallization embodies tcm clinical practice medicine law, is tcm treatment according to syndrome differentiation, the side's of sending medication and the material base for characterizing curative effect.
The it is proposed of this nine kinds of combinations is in the case where curing mainly card and the interpretation of the cause, onset and process of an illness is essentially identical, by the change of drug dose, but compatibility
Relationship is constant, and treatment state of an illness weight is different, and curative effect also changes, and produces various clinical effect.
A kind of Chinese medicine composition that treating arrhythmia cordis is demonstrated by having done a large amount of clinical and animal experiment study
Curative effect, by the economic benefit brought and social benefit.Multinomial data prove a kind of Chinese medicine composition for treating arrhythmia cordis
The general status of atrial fibrillation rat can be improved;Palatelet-selectin content increases in blood plasma when atrial fibrillation, and platelet activation, the present invention can
Reduce palatelet-selectin in rat plasma;The content of TXB2, MMP-9 in atrial fibrillation rat blood serum can be reduced;It lowers in rat blood serum
PAI-I is horizontal, to mitigate the breaking-out of atrial fibrillation;A kind of Chinese medicine composition for treating arrhythmia cordis can lower the Ca of cardiac muscular tissue2+-
ATP enzyme genetic transcription reaches calcium overload when improving atrial fibrillation, to delay the generation of atrial electrical remodeling, prevents the work of " AF causes AF "
With;A kind of Chinese medicine composition that treating arrhythmia cordis can be substantially reduced Cx40 gene expression doses, can reduce the multiple folding in atrium
The generation returned;The expression that kinases 2 (ERK2) mRNA is adjusted outside atrial fibrillation rat heart muscle histocyte can be raised;It can lower
Atrial fibrillation rat heart muscle tissue L-type calcium channel mRNA expression is horizontal;And it is effectively improved the variation of atrial fibrillation myocardial ultrastructure.
Clinical observation proves that a kind of Chinese medicine composition for treating arrhythmia cordis can improve and restore the overall effective of patient's ventricular late potential
Rate up to 79.9%, affirmed by clinical efficacy.The present invention can adjust the compliance of patient's cardiac muscle, under the conditions of increasing myocardial anoxia
Tolerance and myocardial ATP enzyme activity, reduce intra-atrial reentry, stablize myocardial cell membrane, improve cardiac muscle multipole conduction system
Significant protective effect is presented to cardiac muscle in system function.The clinical efficacy for significantly improving patient improves the quality of life of patient, reaches
To antiarrhythmic effect.From different perspectives, different levels, using modern science and technology means and method, with molecular biology
Based on, a kind of mechanism of action of Chinese medicine composition that treating arrhythmia cordis is furtherd investigate and explored, is premature beat and room
The drug therapy quivered provides objective basis, this has the more potential diagnosis of premature beat and atrial fibrillation and generation, the development of predictive disease
Far-reaching application value.
Compared with prior art, trouble can be adjusted by having for a kind of Chinese medicine composition that treating arrhythmia cordis and quality determining method
The compliance of person's cardiac muscle increases the activity of the tolerance and myocardial ATP enzyme under the conditions of myocardial anoxia, reduces intra-atrial reentry, surely
Centering muscle cell membrane, improves the multipole conducting system function of cardiac muscle, significant protective effect is presented to cardiac muscle, hence it is evident that improve patient
Clinical efficacy, improve the quality of life of patient, reach antiarrhythmic effect, from different perspectives, different levels, using the modern times
Scientific and technological means and method are furtherd investigate and are explored to the mechanism of action of drug based on molecular biology, are early
It fights and provides objective basis with the drug therapy of atrial fibrillation, this is to the potential diagnosis of premature beat and atrial fibrillation and generation, the development of predictive disease
With more far-reaching application value, clinical observation proves that the present invention can improve and restore the overall efficiency of patient's ventricular late potential
Up to 79.9%, the advantages that clinical efficacy is obtained certainly, will be widely used in technical field of Chinese medicine.
Description of the drawings
The following describes the present invention in detail with reference to the accompanying drawings and embodiments.
Fig. 1 be the present invention rat modeling before electrocardiogram.
Fig. 2 be the present invention rat modeling after instant electrocardiogram.
Fig. 3 be the present invention rat modeling after enter a group electrocardiogram.
Fig. 4 is each group rat heart muscle tissue Ca of the present invention2+- ATP mRNA express PCR product agarose gel electrophoresis knot
Fruit is schemed.
Fig. 5 is each group rat heart muscle tissue Cx40 gene expression PCR product agarose gel electrophoresis result figures of the present invention.
Fig. 6 is the electrophoretogram one of the L-type calcium channel mRNA expression Long-term change trend of the present invention.
Fig. 7 is the electrophoretogram two of the L-type calcium channel mRNA expression Long-term change trend of the present invention.
Fig. 8 is the electrophoretogram one of extracellular regulated kinases 2 (ERK2) mRNA expression Long-term change trends of the present invention.
Fig. 9 is the electrophoretogram two of extracellular regulated kinases 2 (ERK2) mRNA expression Long-term change trends of the present invention.
Figure 10 be the present invention Electronic Speculum under each group rat heart muscle tissue hyper-microstructure situation normal control group picture one.
Figure 11 be the present invention Electronic Speculum under each group rat heart muscle tissue hyper-microstructure situation normal control group picture two.
Figure 12 be the present invention Electronic Speculum under each group rat heart muscle tissue hyper-microstructure situation model comparison group picture one.
Figure 13 be the present invention Electronic Speculum under each group rat heart muscle tissue hyper-microstructure situation model comparison group picture two.
Figure 14 be the present invention Electronic Speculum under each group rat heart muscle tissue hyper-microstructure situation Chinese herbs group figure one.
Figure 15 be the present invention Electronic Speculum under each group rat heart muscle tissue hyper-microstructure situation Chinese herbs group figure two.
Figure 16 be the present invention Electronic Speculum under each group rat heart muscle tissue hyper-microstructure situation western medicine group figure one.
Figure 17 be the present invention Electronic Speculum under each group rat heart muscle tissue hyper-microstructure situation western medicine group figure two.
Specific implementation mode
Reference attached drawing,
Embodiment one
(1) honey-fried licorice root 30g, Radix Rehmanniae 25g, ginseng 20g, Radix Astragali 30g are taken in prescription ratio, 70% second measured with 10 times
Alcohol, twice, 2 hours every time, filtering, filtrate merged heating and refluxing extraction, and recycling ethyl alcohol obtains liquid I;
(2) Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 20g are taken in prescription ratio, impregnated 30 minutes, by step (1)
The middle gained dregs of a decoction are added, common decocting 2 times, for the first time 12 times of water, decoct 2 hours, and filtration obtains liquid II, second of 8 times of water,
It decocts 1.5 hours, filtration obtains liquid III, collects distillate twice, obtains liquid IV;
(3) liquid I, II, III, IV is merged, mixing carries out coarse filtration and refined filtration, refined filtration liquid triple effect with plate and frame filter press
It is 1.15 that energy-saving concentrator, which is concentrated into relative density, temperature 60 C;Concentrate spray drying process, feed speed 6000ml/
Min, centrifugal speed 6000r/min, 120 DEG C of inlet air temperature, prepare extract powder;20% dextrin mixing is added in cream powder, with 80%
Ethanol wet is pelletized, wet granular boiled bed drying, 75 DEG C of wind-warm syndrome;Beta-cyclo dextrin included compound powder, whole grain is added;Inspection is sub-packed in
In aluminium plastic membrane bag, 3g is often wrapped, both obtains finished dosage form, and pill, capsule, decoction, powder, electuary, granule or mouth is made
Take liquid.
A kind of Chinese medicine composition that treating arrhythmia cordis and drug quality differentiate detection method, according to the animal of embodiment one
Laboratory report:
Experimental method:Select the healthy male Wistar big white mouse 100, weight 250-300g of 10-12 week old, animal one
As in good condition, fur gloss, feed, adaptable fed after a week modeling normal with activity.It is mixed using calcium chloride-acetylcholine
Close the animal model that liquid establishes atrial fibrillation in such a way that caudal vein is administered.As stated above after modeling, screening has typical atrial fibrillation
The rat of Electrocardiogram Feature 30, is randomly divided into, totally 3 groups, average every group of 10 rats.In addition no progress modeling processing is just
10 rats of normal control group are four groups altogether.Because there is rats death during medication, therefore every group of random selection 8 is only into row index
Measurement.Each group animal is raised under equal conditions.Normal group, model group gavage the physiological saline of same isometric(al) once a day;
By people's mouse dose lonvestion, dosage (g) × coefficient (0.081)/required the weight of animals of the people for dosage (g/Kg)=provide
(Kg)。
Invigorating Qi Chinese herbs group:It gavages and is equivalent to 16.2g/kg/d crude drugs, once a day;Western medicine group fills
Clothes are equivalent to the Verapamil of 4.5mg/kg/d crude drugs, once a day.Share medicine 4 weeks.Indices are measured after 4 weeks.It retouches respectively
Note rat modeling before, after modeling, enter a group electrocardiogram after modeling;Observe the ordinary circumstance of rat:Including the state of mind, hair color, mouth
Lip, tongue nature, breathing, the variation etc. of heart rate.The level of palatelet-selectin in serum is measured using double crush syndrome method.Using
14.0 software packages of SPSS are for statistical analysis.
(1) rat modeling electrocardiogram
Fig. 1 be the present invention rat modeling before electrocardiogram.Fig. 2 be the present invention rat modeling after instant electrocardiogram.Fig. 3 is
Enter a group electrocardiogram after the rat modeling of the present invention.
(2) each group rat general state is observed
The visible hair color of normal rats is pure white, and fur Smooth and moist, expression is normal, and body movement is flexible, and breathing is steady, shape
State is good.
The visible spirit of atrial fibrillation rat is not good enough after modeling, and happiness is tired sleeping, and respiratory rate is accelerated, and claw has livid purple color, skin with lip
Hair is not so good as preoperative Smooth and moist, and breathing, heart rate number are obviously accelerated.After the four weeks of administration, Chinese medicine group, Western medicine Verapamil pair
It is clearly better according to the rat state of group, appetite increases, and activity is flexibly;Model group state is not good enough earlier above.Prompt Dingxin capsule group and
Verapamil group all has an impact the observation index of AF rats.Because there is rats death during medication, therefore every group of random selection 8
Only into the measurement of row index.
(3) palatelet-selectin situation of change in each group rat blood serum, is shown in Table 4.
Palatelet-selectin situation of change in 4 each group rat blood serum of table
Group | Number of cases | Palatelet-selectin (ng/ml) |
Blank control group | 8 | 51.186±9.571 |
Model control group | 8 | 122.836±12.998* |
Chinese medicine group | 8 | 92.289±16.121Δ# |
Western medicine group | 8 | 98.34±13.451Δ |
Note:Compared with blank group, * P<0.01;Compared with model group,ΔP<0.01;Compared with Verapamil group,#P>
0.05。
It can be seen that palatelet-selectin, in model group and the more significant difference of blank control group, P < 0.01 illustrate that model group is big
Palatelet-selectin content is significantly larger than normal group in mouse serum, prompts when atrial fibrillation that palatelet-selectin content increases in blood plasma, and blood platelet is lived
Change;Palatelet-selectin content is substantially reduced treatment group's (including Western medicine, Chinese medicine group) compared with model group, P < 0.01, illustrates have significantly
Meaning, treatment are effective.Chinese medicine group P compared with western medicine group>0.05, it is not statistically significant, illustrates Chinese medicine and Western medicine Wella
Pa rice is similar with prevention effect to the treatment of atrial fibrillation.
Embodiment two
(1) honey-fried licorice root 30g, Radix Rehmanniae 25g, ginseng 25g, Radix Astragali 25g are taken in prescription ratio, 70% second measured with 10 times
Alcohol, twice, 2 hours every time, filtering, filtrate merged heating and refluxing extraction, and recycling ethyl alcohol obtains liquid I;
(2) Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 25g are taken in prescription ratio, impregnated 30 minutes, by step (1)
The middle gained dregs of a decoction are added, common decocting 2 times, for the first time 12 times of water, decoct 2 hours, and filtration obtains liquid II, second of 8 times of water,
It decocts 1.5 hours, filtration obtains liquid III, collects distillate twice, obtains liquid IV;
(3) liquid I, II, III, IV is merged, mixing carries out coarse filtration and refined filtration, refined filtration liquid triple effect with plate and frame filter press
It is 1.15 that energy-saving concentrator, which is concentrated into relative density, temperature 60 C;Concentrate spray drying process, feed speed 6000ml/
Min, centrifugal speed 6000r/min, 120 DEG C of inlet air temperature, prepare extract powder;20% dextrin mixing is added in cream powder, with 80%
Ethanol wet is pelletized, wet granular boiled bed drying, 75 DEG C of wind-warm syndrome;Beta-cyclo dextrin included compound powder, whole grain is added;Inspection is sub-packed in
In aluminium plastic membrane bag, 3g is often wrapped, both obtains finished dosage form, and pill, capsule, decoction, powder, electuary, granule or mouth is made
Take liquid.
A kind of Chinese medicine composition that treating arrhythmia cordis and drug quality differentiate detection method, according to the animal of embodiment two
Laboratory report:
Experimental method:Select the healthy male Wistar big white mouse 100, weight 250-300g of 10-12 week old, animal one
As in good condition, fur gloss, feed, adaptable fed after a week modeling normal with activity.It is mixed using calcium chloride-acetylcholine
Close the animal model that liquid establishes atrial fibrillation in such a way that caudal vein is administered.As stated above after modeling, screening has typical atrial fibrillation
The rat of Electrocardiogram Feature 30, is randomly divided into, totally 3 groups, average every group of 10 rats.In addition no progress modeling processing is just
10 rats of normal control group are four groups altogether.Because there is rats death during medication, therefore every group of random selection 8 is only into row index
Measurement.Each group animal is raised under equal conditions.Normal group, model group gavage the physiological saline of same isometric(al) once a day;
By people's mouse dose lonvestion, dosage (g) × coefficient (0.081)/required the weight of animals of the people for dosage (g/Kg)=provide
(Kg).Invigorating Qi Chinese herbs group:It gavages and is equivalent to 16.2g/kg/d crude drugs, once a day;Western medicine group gavages
It is equivalent to the Verapamil of 4.5mg/kg/d crude drugs, once a day.Share medicine 4 weeks.After 4 weeks blood is measured using radioimmunology method
Thromboxane B in clear2(TXB2) level.It is for statistical analysis using SPSS14.0 software packages.
TXB in 5 each group rat blood serum of table2The case where
Group | Number of cases | TXB2(X±S) |
Normal group | 8 | 36.39±4.94 |
Model group | 8 | 129.57±16.29* |
Chinese medicine group | 8 | 44.10±4.68** |
Western medicine group | 8 | 70.78±9.56# |
* the P < 0.05 compared with normal group, * * the P < 0.05 compared with model group, # the P < 0.05 compared with Chinese medicine group, with mould
Type group compares P < 0.05.
From table 5:Model group has significant difference (P < 0.01), illustrates model group rats serum compared with normal group
Middle TXB2It more normally organizes statistically significant.Chinese medicine group and Western medicine group are compared with model group, and P < 0.05 are statistically significant;But
Chinese medicine group and Western medicine group compare, and Chinese medicine group is better than Western medicine group (P < 0.05).In this experiment, TXB in the serum of model group2It is high
It is in normal group and statistically significant, when illustrating atrial fibrillation, TXB in serum2Level increases, and Chinese medicine can actually lower serum
Middle TXB2Level, to mitigate the breaking-out of AF.
In 6 each group rat blood serum of table the case where PAI-I
Group | Number of cases | PAⅠ-1(X±S) |
Normal group | 8 | 16.09±5.41 |
Model group | 8 | 49.33±9.10* |
Chinese medicine group | 8 | 19.40±5.14** |
Western medicine group | 8 | 29.61±4.91# |
* the P < 0.05 compared with normal group, * * the P < 0.05 compared with model group, # the P < 0.05 compared with Chinese medicine group, with mould
Type group compares P < 0.05.
From table 6:Model group has significant difference (P < 0.01), illustrates model group rats serum compared with normal group
Middle PA I -1 more normally organizes statistically significant.Chinese medicine group and Western medicine group are compared with model group, and P < 0.05 are statistically significant,
And Chinese medicine group and Western medicine group compare, Chinese medicine group is better than Western medicine group (P < 0.05).In this experiment, PAI-I in the serum of model group
Higher than normal group and statistically significant, when illustrating atrial fibrillation, PAI-I levels increase in serum, and invigorating Qi Chinese medicine
Dingxin capsule can actually lower PAI-I levels in serum, to mitigate the breaking-out of AF.
Embodiment three
(1) honey-fried licorice root 25g, Radix Rehmanniae 30g, ginseng 20g, Radix Astragali 35g are taken in prescription ratio, 70% second measured with 10 times
Alcohol, twice, 2 hours every time, filtering, filtrate merged heating and refluxing extraction, and recycling ethyl alcohol obtains liquid I;
(2) Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 20g are taken in prescription ratio, impregnated 30 minutes, by step (1)
The middle gained dregs of a decoction are added, common decocting 2 times, for the first time 12 times of water, decoct 2 hours, and filtration obtains liquid II, second of 8 times of water,
It decocts 1.5 hours, filtration obtains liquid III, collects distillate twice, obtains liquid IV;
(3) liquid I, II, III, IV is merged, mixing carries out coarse filtration and refined filtration, refined filtration liquid triple effect with plate and frame filter press
It is 1.15 that energy-saving concentrator, which is concentrated into relative density, temperature 60 C;Concentrate spray drying process, feed speed 6000ml/
Min, centrifugal speed 6000r/min, 120 DEG C of inlet air temperature, prepare extract powder;20% dextrin mixing is added in cream powder, with 80%
Ethanol wet is pelletized, wet granular boiled bed drying, 75 DEG C of wind-warm syndrome;Beta-cyclo dextrin included compound powder, whole grain is added;Inspection is sub-packed in
In aluminium plastic membrane bag, 3g is often wrapped, both obtains finished dosage form, and pill, capsule, decoction, powder, electuary, granule or mouth is made
Take liquid.
A kind of Chinese medicine composition that treating arrhythmia cordis and drug quality differentiate detection method, according to the animal of embodiment three
Laboratory report:
Experimental method:Select the healthy male Wistar big white mouse 100, weight 250-300g of 10-12 week old, animal one
As in good condition, fur gloss, feed, adaptable fed after a week modeling normal with activity.It is mixed using calcium chloride-acetylcholine
Close the animal model that liquid establishes atrial fibrillation in such a way that caudal vein is administered.As stated above after modeling, screening has typical atrial fibrillation
The rat of Electrocardiogram Feature 30, is randomly divided into, totally 3 groups, average every group of 10 rats.In addition no progress modeling processing is just
10 rats of normal control group are four groups altogether.Because there is rats death during medication, therefore every group of random selection 8 is only into row index
Measurement.Each group animal is raised under equal conditions.Normal group, model group gavage the physiological saline of same isometric(al) once a day;
By people's mouse dose lonvestion, dosage (g) × coefficient (0.081)/required the weight of animals of the people for dosage (g/Kg)=provide
(Kg).Invigorating Qi Chinese herbs group:It gavages and is equivalent to 16.2g/kg/d crude drugs, once a day;Western medicine group fills
Clothes are equivalent to the Verapamil of 4.5mg/kg/d crude drugs, once a day.Share medicine 4 weeks.It is put to death greatly under narcosis after 4 weeks
Mouse, be stored in after taking left ventricle to be freezed in liquid nitrogen -70 DEG C it is spare.RT-PCR method measures cardiac muscular tissue Ca2+ATP enzyme gene
Expression.It is for statistical analysis using 14.0 software packages of SPSS.
Each group rat heart muscle tissue Ca2+The situation of change of ATP enzyme gene expression:
Ca is measured with RT-PCR method2+- ATP mRNA and β-actin expression, and agarose is carried out to RT-PCR products
Gel electrophoresis produces two light belts, such as Fig. 1:The above is Ca2+- ATP mRNA expressions, and it is below β-actin expression
Situation, then calculate Ca2+The gray density ratio of-ATP mRNA/ β-actin carries out comparison among groups, as shown in table 7.
Fig. 4 is each group rat heart muscle tissue Ca2+- ATP mRNA express PCR product agarose gel electrophoresis result figure.Fig. 4
In 1 be Marka;2,3 be normal group in Fig. 4;4,5 be model group in Fig. 4;6,7 be Chinese medicine group in Fig. 4;8,9 be Western medicine in Fig. 4
Group.
7 each group rat heart muscle tissue Ca of table2+ATP enzyme gene/β-actin expressions
* the P < 0.05 compared with normal group, * * the P < 0.05 compared with model group, # the P < 0.05 compared with Chinese medicine group, with mould
Type group compares P < 0.05.
From table 7:Model group is compared with normal group, and (P < 0.05=, illustrate model group rats Ca to significant difference2 +ATP enzyme gene expression is more normally organized statistically significant.Chinese medicine group and Western medicine group are compared with model group, P < 0.05, have significantly
Statistical significance;But Chinese medicine group and Western medicine group compare, and Chinese medicine group is better than Western medicine group (P < 0.05=.In this experiment, model group
Ca2+ATP enzyme gene expression is higher than normal group and statistically significant, when illustrating atrial fibrillation, the Ca of cardiac muscular tissue2+ATP enzyme
Increase or density increases, and invigorating Qi Chinese medicine can actually lower Ca2+The mRNA of ATP enzyme is expressed, to mitigate AF's
Breaking-out.
Example IV
(1) honey-fried licorice root 25g, Radix Rehmanniae 25g, ginseng 20g, Radix Astragali 30g are taken in prescription ratio, 70% second measured with 10 times
Alcohol, twice, 2 hours every time, filtering, filtrate merged heating and refluxing extraction, and recycling ethyl alcohol obtains liquid I;
(2) Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 40g, safflower 20g, spina date seed 25g are taken in prescription ratio, impregnated 30 minutes, by step (1)
The middle gained dregs of a decoction are added, common decocting 2 times, for the first time 12 times of water, decoct 2 hours, and filtration obtains liquid II, second of 8 times of water,
It decocts 1.5 hours, filtration obtains liquid III, collects distillate twice, obtains liquid IV;
(3) liquid I, II, III, IV is merged, mixing carries out coarse filtration and refined filtration, refined filtration liquid triple effect with plate and frame filter press
It is 1.15 that energy-saving concentrator, which is concentrated into relative density, temperature 60 C;Concentrate spray drying process, feed speed 6000ml/
Min, centrifugal speed 6000r/min, 120 DEG C of inlet air temperature, prepare extract powder;20% dextrin mixing is added in cream powder, with 80%
Ethanol wet is pelletized, wet granular boiled bed drying, 75 DEG C of wind-warm syndrome;Beta-cyclo dextrin included compound powder, whole grain is added;Inspection is sub-packed in
In aluminium plastic membrane bag, 3g is often wrapped, both obtains finished dosage form, and pill, capsule, decoction, powder, electuary, granule or mouth is made
Take liquid.
A kind of Chinese medicine composition that treating arrhythmia cordis and drug quality differentiate detection method, according to the animal of example IV
Laboratory report:
Experimental method:Select the healthy male Wistar big white mouse 100, weight 250-300g of 10-12 week old, animal one
As in good condition, fur gloss, feed, adaptable fed after a week modeling normal with activity.It is mixed using calcium chloride-acetylcholine
Close the animal model that liquid establishes atrial fibrillation in such a way that caudal vein is administered.As stated above after modeling, screening has typical atrial fibrillation
The rat of Electrocardiogram Feature 30, is randomly divided into 3 groups, average every group of 10 rats.In addition no carry out the normal of modeling processing
10 rats of control group are four groups altogether.Because there is rats death during medication, therefore every group of random selection 8 is only into row index
It measures.Each group animal is raised under equal conditions.Normal group, model group gavage the physiological saline of same isometric(al) once a day;It presses
People's mouse dose lonvestion, dosage (g) × coefficient (0.081)/required the weight of animals (Kg) of the people for dosage (g/Kg)=provide.
Invigorating Qi Chinese herbs group:It gavages and is equivalent to 16.2g/kg/d crude drugs, once a day;Western medicine group gavages quite
In the Verapamil of 4.5mg/kg/d crude drugs, once a day.Share medicine 4 weeks.Rat is put to death under narcosis after 4 weeks, takes a left side
Ventricle be stored in after being freezed in liquid nitrogen -70 DEG C it is spare.RT-PCR method measures cardiac muscular tissue's Cx40 gene expressions.Using
14.0 software packages of SPSS are for statistical analysis.
The situation of change of each group rat heart muscle tissue Cx40 gene expressions:
Cx40 gene expressions and β-actin expression are measured with RT-PCR method, and agarose is carried out to RT-PCR products
Gel electrophoresis produces two light belts, such as Fig. 2:The above is Cx40 expression conditions, and is below β-actin expressions,
The gray density ratio for calculating Cx40mRNA/ β-actin again carries out comparison among groups, as shown in table 8.
Fig. 5 is each group rat heart muscle tissue Cx40 gene expression PCR product agarose gel electrophoresis result figures of the present invention.
1 is Marka in Fig. 5;2,3 be normal group in Fig. 5;4,5 be model group in Fig. 5;6,7 be Chinese medicine group in Fig. 5;8,9 be west in Fig. 5
Medicine group.
8 each group rat heart muscle tissue Cx40 genes of table/β-actin expressions
Group | Number of cases | Intensity ratio |
Normal group | 8 | 0.31±5.88×10-2 |
Model group | 8 | 2.08±42.66×10-2* |
Chinese medicine group | 8 | 0.92±11.7×10-2** |
Western medicine group | 8 | 1.16±8.21×10-2# |
* the P < 0.05 compared with normal group, * * the P < 0.05 compared with model group, # the P < 0.05 compared with Chinese medicine group, with mould
Type group compares P < 0.05.
From table 8:Model group is compared with normal group, and (P < 0.05=, illustrate model group rats to significant difference
Cx40 gene expressions are more normally organized statistically significant.Compared with model group, P < 0.05 have statistics for Chinese medicine group and Western medicine group
Meaning;But Chinese medicine group and Western medicine group compare, and Chinese medicine group is better than Western medicine group (P < 0.05=.In this experiment, the Cx40 of model group
Gene expression is higher than normal group and statistically significant, when illustrating atrial fibrillation, the Cx40 gene expressions of cardiac muscular tissue increase or
Density increases, and invigorating Qi Chinese medicine can actually lower Cx40 gene expressions, to mitigate the breaking-out of AF.
Embodiment five
(1) honey-fried licorice root 30g, Radix Rehmanniae 25g, ginseng 20g, Radix Astragali 30g are taken in prescription ratio, 70% second measured with 10 times
Alcohol, twice, 2 hours every time, filtering, filtrate merged heating and refluxing extraction, and recycling ethyl alcohol obtains liquid I;
(2) Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 35g, safflower 25g, spina date seed 25g are taken in prescription ratio, impregnated 30 minutes, by step (1)
The middle gained dregs of a decoction are added, common decocting 2 times, for the first time 12 times of water, decoct 2 hours, and filtration obtains liquid II, second of 8 times of water,
It decocts 1.5 hours, filtration obtains liquid III, collects distillate twice, obtains liquid IV;
(3) liquid I, II, III, IV is merged, mixing carries out coarse filtration and refined filtration, refined filtration liquid triple effect with plate and frame filter press
It is 1.15 that energy-saving concentrator, which is concentrated into relative density, temperature 60 C;Concentrate spray drying process, feed speed 6000ml/
Min, centrifugal speed 6000r/min, 120 DEG C of inlet air temperature, prepare extract powder;20% dextrin mixing is added in cream powder, with 80%
Ethanol wet is pelletized, wet granular boiled bed drying, 75 DEG C of wind-warm syndrome;Beta-cyclo dextrin included compound powder, whole grain is added;Inspection is sub-packed in
In aluminium plastic membrane bag, 3g is often wrapped, both obtains finished dosage form, and pill, capsule, decoction, powder, electuary, granule or mouth is made
Take liquid.
A kind of Chinese medicine composition that treating arrhythmia cordis and drug quality differentiate detection method, according to the animal of embodiment five
Laboratory report:
Experimental method:Select the healthy male Wistar big white mouse 100, weight 250-300g of 10-12 week old, animal one
As in good condition, fur gloss, feed, adaptable fed after a week modeling normal with activity.It is mixed using calcium chloride-acetylcholine
Close the animal model that liquid establishes atrial fibrillation in such a way that caudal vein is administered.As stated above after modeling, screening has typical atrial fibrillation
The rat of Electrocardiogram Feature 30, is randomly divided into, totally 3 groups, average every group of 10 rats.In addition no progress modeling processing is just
10 rats of normal control group are four groups altogether.Because there is rats death during medication, therefore every group of random selection 8 is only into row index
Measurement.Each group animal is raised under equal conditions.Normal group, model group gavage the physiological saline of same isometric(al) once a day;
By people's mouse dose lonvestion, dosage (g) × coefficient (0.081)/required the weight of animals of the people for dosage (g/Kg)=provide
(Kg).Invigorating Qi Chinese herbs group:It gavages and is equivalent to 16.2g/kg/d crude drugs, once a day;Western medicine group gavages
It is equivalent to the Verapamil of 4.5mg/kg/d crude drugs, once a day.Share medicine 4 weeks.Rat is put to death under narcosis after 4 weeks,
Be stored in after taking left ventricle to be freezed in liquid nitrogen -70 DEG C it is spare.RT-PCR method measures cardiac muscular tissue's L-type calcium channel gene table
It reaches and extracellular regulated kinases 2 (EPK2) gene expression.For statistical analysis using 14.0 software packages of SPSS, comparison among groups are used
Variance analysis, if heterogeneity of variance is examined using Dunnett.
(1) influence that invigorating Qi Chinese medicine expresses experimental AF rat heart muscles ERK2, LTCC mRNA
The influence (X scholar s) that invigorating Qi Chinese medicine expresses experimental AF rat heart muscles ERK2, LTCC mRNA
The influence (X scholar s) that 9 invigorating Qi Chinese medicine of table expresses experimental AF rat heart muscles ERK2, LTCC mRNA
Group | ERK2mRNA/β-actin mRNA | LTCCmRNA/β-actin mRNA |
Blank control group | 0.23458±0.03908 | 0.80578±0.05135 |
Model control group | 0.51158±0.05408* | 0.31592±0.04408* |
Dingxin capsule group | 0.26824±0.02688Δ# | 0.70348±0.03878Δ# |
Verapamil group | 0.49709±0.04740 | 0.61867±0.03098Δ |
Note:Compared with blank group, * P<0.05;Compared with model group,ΔP<0.05;Compared with Verapamil group,#P<
0.05。
(2) L-type calcium channel mRNA expression Long-term change trend
Model control group rat reduces compared with blank control group L-type calcium channel mRNA expression level, and two groups are compared with notable
Sex differernce (P<0.05).It is invigorating Qi Chinese herbs group, Verapamil intervention group, apparent compared with model control group
Improve the state (P that L-type calcium channel mRNA expression level reduces in atrial fibrillation rat atrial tissue<0.05), dry with Verapamil
Pre- group compares, and invigorating Qi Chinese herbs group curative effect is better than Verapamil intervention group (P<0.05).
Fig. 6 is the electrophoretogram one of the L-type calcium channel mRNA expression Long-term change trend of the present invention.1,2 be normal group in Fig. 6;Figure
3,4 be model group in 6;5,6 be Chinese medicine group in Fig. 6;7,8 be Western medicine group in Fig. 6.
Fig. 7 is the electrophoretogram two of the L-type calcium channel mRNA expression Long-term change trend of the present invention.1,2 be normal group in Fig. 7;Figure
3,4 be model group in 7;5,6 be Chinese medicine group in Fig. 7;7,8 be Western medicine group in Fig. 7.
(3) extracellular regulated kinases 2 (ERK2) mRNA expresses Long-term change trend
Expression of the model control group rat compared with blank control group extracellular regulated kinases 2 (ERK2) mRNA increases, in
The expression of medicine treatment group extracellular regulated kinases 2 (ERK2) mRNA reduces, hence it is evident that improves in atrial fibrillation rat atrial tissue
Raised state (the P of expression of extracellular regulated kinases 2 (ERK2) mRNA<0.05), Verapamil intervention group is to extracellular
The raised state of expression for adjusting kinases 2 (ERK2) mRNA is not improved.
Fig. 8 is the electrophoretogram one of extracellular regulated kinases 2 (ERK2) mRNA expression Long-term change trends of the present invention.1,2 is just
Normal group, 3,4 be model group, and 5,6 be Chinese medicine group, and 7,8 be Western medicine group.
Fig. 9 is the electrophoretogram two of extracellular regulated kinases 2 (ERK2) mRNA expression Long-term change trends of the present invention.1,2 is just
Normal group, 3,4 be model group, and 5,6 be Chinese medicine group, and 7,8 be Western medicine group.
Embodiment six
(1) honey-fried licorice root 40g, Radix Rehmanniae 25g, ginseng 25g, Radix Astragali 30g are taken in prescription ratio, 70% second measured with 10 times
Alcohol, twice, 2 hours every time, filtering, filtrate merged heating and refluxing extraction, and recycling ethyl alcohol obtains liquid I;
(2) Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 25g are taken in prescription ratio, impregnated 30 minutes, by step (1)
The middle gained dregs of a decoction are added, common decocting 2 times, for the first time 12 times of water, decoct 2 hours, and filtration obtains liquid II, second of 8 times of water,
It decocts 1.5 hours, filtration obtains liquid III, collects distillate twice, obtains liquid IV;
(3) liquid I, II, III, IV is merged, mixing carries out coarse filtration and refined filtration, refined filtration liquid triple effect with plate and frame filter press
It is 1.15 that energy-saving concentrator, which is concentrated into relative density, temperature 60 C;Concentrate spray drying process, feed speed 6000ml/
Min, centrifugal speed 6000r/min, 120 DEG C of inlet air temperature, prepare extract powder;20% dextrin mixing is added in cream powder, with 80%
Ethanol wet is pelletized, wet granular boiled bed drying, 75 DEG C of wind-warm syndrome;Beta-cyclo dextrin included compound powder, whole grain is added;Inspection is sub-packed in
In aluminium plastic membrane bag, 3g is often wrapped, both obtains finished dosage form, and pill, capsule, decoction, powder, electuary, granule or mouth is made
Take liquid.
A kind of Chinese medicine composition that treating arrhythmia cordis and drug quality differentiate detection method, according to the animal of embodiment six
Laboratory report:
Experimental method:Select the healthy male Wistar big white mouse 100, weight 250-300g of 10-12 week old, animal one
As in good condition, fur gloss, feed, adaptable fed after a week modeling normal with activity.It is mixed using calcium chloride-acetylcholine
Close the animal model that liquid establishes atrial fibrillation in such a way that caudal vein is administered.As stated above after modeling, screening has typical atrial fibrillation
The rat of Electrocardiogram Feature 30, is randomly divided into, totally 3 groups, average every group of 10 rats.In addition no progress modeling processing is just
10 rats of normal control group are four groups altogether.Because there is rats death during medication, therefore every group of random selection 8 is only into row index
Measurement.Each group animal is raised under equal conditions.Normal group, model group gavage the physiological saline of same isometric(al) once a day;
By people's mouse dose lonvestion, dosage (g) × coefficient (0.081)/required the weight of animals of the people for dosage (g/Kg)=provide
(Kg).Chinese herbs group:It gavages and is equivalent to 16.2g/kg/d crude drugs, once a day;Western medicine group, which gavages, is equivalent to 4.5mg/
The Verapamil of kg/d crude drugs, once a day.Share medicine 4 weeks.Rat is put to death under narcosis after 4 weeks, takes left ventricle in liquid
In nitrogen freeze after be stored in -70 DEG C it is spare.Rat atrial is taken to be cut into 1mm3Several pieces of size cleans blood with ice physiological saline,
Again with 2.5% glutaraldehyde, 1% osmic acid OsO4Dual fixation, alcohol, acetone serial dehydration, epoxy resin Epon812 embeddings, system
At ultra-thin section, the double dyeing of uranium, lead are used later, with the ultra microstructure of transmission electron microscope observing cardiac muscular tissue.
Each group rat heart muscle tissue hyper-microstructure situation is as follows under Electronic Speculum:(see attached drawing 10-17)
Normal group (Figure 10,11):Visible cardiac muscle cell's band is clear under Electronic Speculum, and muscle corpuscle is located under muscle fibril
Side, sarcoplasm mitochondrial quantity is more, the uniform no swelling of size and form, and ridge arrangement is close, and muscle fibril traveling is neat, adjacent flesh
There are intercalated disc, intercalated disc to be located at the both ends of cell between fiber.
Model group (Figure 12,13):It can be seen that Myocardial ultrastructure has major injury, cardiac muscle cell's mitochondrial swelling, ridge
Fracture is in vacuole sample, and karyopyknosis is in irregular type, and electron density reduces, and metachromatin accumulates in the periphery of core in core, it is seen that
Kernel, muscle fibril is disorganized, muscle segment is broken, and intercalated disc is discontinuous, existing rough surfaced endoplasmic reticulum (RER) in sarcoplasmic reticulum, it is seen that glycogen particle,
Fat drips etc..
The visible cardiac muscle cell's muscle fibril of Chinese herbs group (Figure 14,15) is normal, arrangement is close, and muscle corpuscle is normal, line
Plastochondria volume becomes smaller, and shape owes rule, and ridge is intensive, quantity is more, relatively with normal group.
The visible cardiac muscle cell's muscle fibril of western medicine group (Figure 16,17) is close to normally, and arrangement is closer, and muscle corpuscle connects
Close normal, mitochondria volume becomes smaller, and shape is irregular, and no fiber is disorderly, is broken and lacks, and is closer to normal group.
Embodiment seven
(1) honey-fried licorice root 25g, Radix Rehmanniae 25g, ginseng 20g, Radix Astragali 30g are taken in prescription ratio, 70% second measured with 10 times
Alcohol, twice, 2 hours every time, filtering, filtrate merged heating and refluxing extraction, and recycling ethyl alcohol obtains liquid I;
(2) Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 35g, safflower 25g, spina date seed 40g are taken in prescription ratio, impregnated 30 minutes, by step (1)
The middle gained dregs of a decoction are added, common decocting 2 times, for the first time 12 times of water, decoct 2 hours, and filtration obtains liquid II, second of 8 times of water,
It decocts 1.5 hours, filtration obtains liquid III, collects distillate twice, obtains liquid IV;
(3) liquid I, II, III, IV is merged, mixing carries out coarse filtration and refined filtration, refined filtration liquid triple effect with plate and frame filter press
It is 1.15 that energy-saving concentrator, which is concentrated into relative density, temperature 60 C;Concentrate spray drying process, feed speed 6000ml/
Min, centrifugal speed 6000r/min, 120 DEG C of inlet air temperature, prepare extract powder;20% dextrin mixing is added in cream powder, with 80%
Ethanol wet is pelletized, wet granular boiled bed drying, 75 DEG C of wind-warm syndrome;Beta-cyclo dextrin included compound powder, whole grain is added;Inspection is sub-packed in
In aluminium plastic membrane bag, 3g is often wrapped, both obtains finished dosage form, and pill, capsule, decoction, powder, electuary, granule or mouth is made
Take liquid.
A kind of Chinese medicine composition that treating arrhythmia cordis and drug quality differentiate detection method, according to the animal of embodiment seven
Laboratory report:
Experimental method:Select the healthy male Wistar big white mouse 100, weight 250-300g of 10-12 week old, animal one
As in good condition, fur gloss, feed, adaptable fed after a week modeling normal with activity.It is mixed using calcium chloride-acetylcholine
Close the animal model that liquid establishes atrial fibrillation in such a way that caudal vein is administered.As stated above after modeling, screening has typical atrial fibrillation
The rat of Electrocardiogram Feature 30, is randomly divided into, totally 3 groups, average every group of 10 rats.In addition no progress modeling processing is just
10 rats of normal control group are four groups altogether.Because there is rats death during medication, therefore every group of random selection 8 is only into row index
Measurement.Each group animal is raised under equal conditions.Normal group, model group gavage the physiological saline of same isometric(al) once a day;
By people's mouse dose lonvestion, dosage (g) × coefficient (0.081)/required the weight of animals of the people for dosage (g/Kg)=provide
(Kg).Chinese herbs group:It gavages and is equivalent to 16.2g/kg/d crude drugs, once a day;Western medicine group, which gavages, is equivalent to 4.5mg/
The Verapamil of kg/d crude drugs, once a day.Share medicine 4 weeks.Rat blood serum is measured using double-antibody sandwich ABC~ELISA method
The level of middle MMP-9.Anti- rat MMP-9 monoclonal antibodies are coated on ELISA Plate, and the MMP-9 in standard items and sample is combined with monoclonal antibody,
Biotinylated anti-rat MMP-9 is added, forms immune complex connection onboard, the Strep of horseradish peroxidase-labeled
Ta-vidin is combined with biotin, and zymolyte OPO is added, yellow occurs, adds terminate liquid, after darkening, is surveyed at 492nm
OD values, MMP-9 concentration is directly proportional to OD values, and the concentration of sample MMP-9 is found out by drawing standard curve.
The variation (X scholar s) of MMP-9 in 10 each group rat blood serum of table
Group | Number of cases | MMP-9(X±S) |
Normal group | 8 | 1.840±0.280 |
Model group | 8 | 4.060±1.040** |
Chinese medicine group | 8 | 2.325±1.450△ |
Western medicine group | 8 | 3.245±1.635#* |
Note:Compared with normal group, * P < 0.05;Compared with model group, △ P < 0.05;Compared with Chinese medicine group, #P < 0.05
A kind of quality determining method of Chinese medicine composition for treating arrhythmia cordis is as follows:
One, instrument and reagent
LC-10P liquid phase pump LC-10UV UV detector, big Liaanjiang county Shen separation science Technology Co., Ltd. production;Chromatographic column
1 (Hypersil), Dalian Yi Lite Co., Ltds provide;5 μ, 4.6mm × 200mm;Chromatographic column 2 (Spherigel), big Liaanjiang county
Shen separation science Co., Ltd provides;5 μ, 4.6mm × 200mm;Agents useful for same acetonitrile is chromatographically pure, and Shandong king's Yu industry is limited
Company Yucheng chemical plant;Water is double distilled water, and other reagents are that analysis is pure;Ginsenoside Rg1's reference substance, Chinese drug biology system
Product examine is fixed to be provided, and assay is used, lot number 0703-9812;
Two, method and result
1, thin layer differentiates
(1) thin layer of Radix Salviae Miltiorrhizae differentiates
This product content 2g is taken, water 50ml, ultrasonic extraction 30 minutes is added to let cool, centrifuges, supernatant is taken, with dilute hydrochloric acid tune
Section pH value is 1-2, is extracted 2 times, each 20ml with ethyl acetate, merges ethyl acetate liquid, is evaporated, it is molten that residue adds methanol 1ml to make
Solution, as test solution;Protocatechualdehyde reference substance separately is taken, adds methanol that solution of every 1ml containing 1mg is made, product are molten as a contrast
Liquid;It is tested according to thin-layered chromatography, with reference to Chinese Pharmacopoeia one annex VIB of version in 2000, draws 5 μ l of reference substance solution, test sample
Solution 10-20 μ l, put on the silica gel g thin-layer plate in same using 0.4% sodium carboxymethylcellulose as binder, respectively with chloroform-
Acetone-formic acid is solvent, chloroform:Acetone:The ratio of formic acid is 8:1:1, it is unfolded, takes out, dry, sprays with 5% ferric trichloride
Ethanol solution, it is clear that hot wind is blown to spot development, sets and is inspected under daylight;In test sample chromatography, corresponding with reference substance chromatography
On position, the spot of same color is shown;
(2) thin layer of Radix Astragali differentiates
This product content 3g is taken, methanol 30ml is added, is ultrasonically treated 30 minutes, lets cool, is filtered, filtrate is evaporated, and residue adds water
20ml makes dissolving, is transferred in separatory funnel, adds water saturated n-butanol shaking extraction 2 times, is followed successively by 30ml, 20ml, merges
N-butanol extracting liquid is washed 2 times, each 20ml with 1% sodium hydroxide solution, discards lye, then the washing being saturated with n-butanol
It washs 2 times, each 15ml, discards aqueous, n-butanol liquid is evaporated, and residue adds methanol 1-2ml to make dissolving, as test solution;Separately
Astragaloside IV reference substance is taken, adds methanol that solution of every 1ml containing 0.5mg is made, as a contrast product solution;It is tried according to thin-layered chromatography
It tests, with reference to one VI B of annex of China's coastal port, draws each 5 μ l of above two solution, put respectively thin in same silica G
On laminate, using 10 DEG C of overnight lower layer's solution arranged below of chlorofonn-ethylacetate-methanol-water as solvent, chloroform:Acetic acid second
Ester:Methanol:The ratio of water is 15: 40: 22: 10, is unfolded, and takes out, dries, and spray is heated with 10% ethanol solution of sulfuric acid, at 105 DEG C
It is clear to spot development;In test sample chromatography, on position corresponding with reference substance chromatography, the spot of same color is shown;
(3) thin layer of spina date seed differentiates
This product content 4g is taken, water 50ml, ultrasonic extraction 30 minutes is added to let cool, centrifuges, takes supernatant, use water saturated
N-butanol extracts three times, and each 25ml merges n-butanol liquid, is extracted 2 times, each 50ml with ammonia solution, discards ammonia solution, positive fourth
Alcohol liquid is extracted 2 times, each 30ml with distilled water, discards aqueous solution, and n-butanol liquid is evaporated, and residue adds methanol 1ml to make dissolving, as
Test solution;Saponin A reference substance separately is taken, adds methanol that solution of every 1ml containing 1mg is made, as a contrast product solution.According to
Thin-layered chromatography is tested, and with reference to Chinese Pharmacopoeia version one in 2000, annex VI B draw each 5-10 μ l of above two solution, point
Other point is on same silica gel g thin-layer plate, using 10 DEG C of lower layer's solution arranged below of chloroform-methanol-water as solvent, chloroform:First
Alcohol:The ratio of water is 65:35:10, it is unfolded, takes out, dry, sprays with 1% vanillic aldehyde concentrated sulfuric acid solution, hot wind is blown to spot development
Clearly, it sets and is inspected under daylight;In test sample chromatography, on the corresponding position of product chromatography, the spot of same color 1 is shown;
2, assay
(1) chromatographic condition:
Chromatographic column 1 (Hypersil):5 μ, 4.6mm × 200mm;Chromatographic column 2 (Spherigel):5 μ, 4.6mm × 200mm;
It is filler with octadecylsilane chemically bonded silica;- 0.05% phosphoric acid of acetonitrile is mobile phase;Acetonitrile:The ratio of 0.05% phosphoric acid
It is 20:80, Detection wavelength 203nm;
(2) preparation of reference substance solution:
Precision weighs ginsenoside Rg1 reference substance 10.78mg, is placed in 10ml volumetric flasks, methanol is added to make it dissolve in right amount
And it is diluted to scale, product solution as a contrast after shaking up;Precision draws above-mentioned reference substance solution 2.5ml, is placed in 5ml volumetric flasks
In, add methanol dilution to scale, product dilute solution as a contrast after shaking up, a concentration of 0.539mg/ml of dilute solution;
(3) preparation of test solution:
The a small amount of content of this product is taken, it is finely ground, take 2g, it is accurately weighed and water-saturated n-butanol 50ml is added, it is weighed heavy again
Amount, ultrasonic extraction 30 minutes are stood overnight, and twice ultrasonic extracts 30 minutes, and weighed weight supplies less loss with water-saturated n-butanol
Weight, filtration discards primary filtrate, collects subsequent filtrate;Precision draws subsequent filtrate 25ml, sets in separatory funnel, with 0.5% hydrogen
Aqueous solution of sodium oxide washs 2 times, each 10ml, merges butanol solution, and the water 15ml being saturated with n-butanol is washed 1 time, is discarded
Water lotion, butanol solution water bath method;Residue adds methanol to make to be dissolved in 25ml measuring bottles, adds methanol dilution to scale, shakes up,
It is filtered to obtain the final product with miillpore filter, empty a diameter of 0.45 μm of the net of miillpore filter;
(4) selection of Detection wavelength:
Ginsenoside Rg1's reference substance solution 50 μ l, solution concentration 1.078mg/ml are taken, adds methanol about 5ml, uses Shimadzu
UV-260 is scanned in 400-200nm wave-length coverages, and UV absorption figure is shown in Fig. 1, can be seen that ginseng from UV absorption Fig. 1
Saponin(e Rg1 has absorption peak in 203nm;Therefore select 203nm for ginsenoside Rg1's assay wavelength;
(5) ginsenoside Rg1's reference substance linear relationship is investigated:
Accurate 2 μ l of ginsenoside Rg1's reference substance dilute solution, 4 μ l, 6 μ l, 8 μ l and 10 μ l, the solution concentration drawn is respectively
1.078mg/ml is injected separately into liquid chromatograph, measures ginsenoside Rg1's chromatographic peak peak area, sample size and peak area
Relationship is shown in Table 1;
1 ginsenoside Rg1's reference substance sample size of table and peak area relationship
Sample size μ g | 2.156 | 4.312 | 6.468 | 8.624 | 10.078 |
Peak area | 10202387 | 22357595 | 32868559 | 45702492 | 56099805 |
Calibration curve equation is Y=9.163 × 10-8X+1.074×10-2R=0.9997;
Sample introduction is ranging from:2.156 μ of μ g~10.078 g;
(6) precision test:
20,090801 sample of lot number is taken, it is finely ground, 2g is taken, it is accurately weighed, by test liquid preparation side under " assay " item
Method is tested, and precision draws 5 μ l of test liquid, is amounted to 5 parts, is injected separately into liquid chromatograph, and ginsenoside Rg1's peak area point is measured
Not Wei 20254816,20722368,19968224,20929208,20274486, relative standard deviation 1.90%;
(7) blank test:
Recipe quantity medicinal material is taken, ginseng is removed, negative controls are made by preparation process, then press and tried under " assay " item
It tests, prepares the negative controls solution for lacking ginseng crude drug;By negative controls solution, test solution and each 5 μ of reference substance solution
L is injected separately into liquid chromatograph, and measurement result shows that negative fluid has no phase at ginsenoside Rg1's chromatographic peak retention time
Impurity peaks are answered to interfere;
(8) stability test:
20,090801 sample of lot number is taken, it is finely ground, 2g is taken, it is accurately weighed, by test liquid preparation side under " assay " item
Method is tested, and when test liquid is placed 0,4,8 and 12 hour, draws test liquid and each 5 μ of ginsenoside Rg1's reference substance solution
L is injected separately into liquid chromatograph, and it is respectively 20254816,20557692,20527968,20977204 to measure peak area, phase
It is 1.45% to standard deviation;From test result it is found that test liquid is placed 12 hours, Determination of Content of Ginsenoside Rg_1 is basicly stable.From
The above results are it is found that this assay method, test solution precision are good;
(9) reappearance test:
20,090801 sample of lot number is taken, it is finely ground, 2g is taken, it is accurately weighed, by test liquid preparation side under " assay " item
Method is tested, Determination of Content of Ginsenoside Rg_1 in determination sample, and result is:8.86,8.98,9.08,9.02,8.80mg/, averagely contain
Amount is 8.94mg/, relative standard deviation 1.29%;From test result it is found that Determination of Content of Ginsenoside Rg_1 measures reproducibility examination
It tests and meets regulation;
(10) sample recovery rate is tested:
20,090801 sample of lot number is taken, it is finely ground, 1g is taken, it is accurately weighed, by test liquid preparation side under " assay " item
Method is tested, and amounts to 5 parts, and difference is accurate to be added ginsenoside Rg1 reference substance 17mg, by being tested under " assay " item, measures and adds
Determination of Content of Ginsenoside Rg_1 in standard specimen product calculates, obtains the rate of recovery of this content assaying method ginsenoside Rg1;Its test result
It is shown in Table 2;
2 Determination of Content of Ginsenoside Rg_1 of table measures recovery test result
From above-mentioned recovery test result it is found that this method rate of recovery is good;
(11) Determination of Content of Ginsenoside Rg_1 measures in sample:
Each 20 of the sample of different lot numbers is taken, it is finely ground, 2g is taken, it is accurately weighed, by method test under " assay " item, survey
Determine Determination of Content of Ginsenoside Rg_1, calculates, the result is shown in tables 3;
Determination of Content of Ginsenoside Rg_1 measurement result in 3 sample of table amounts to 10 batches
Determination of Content of Ginsenoside Rg_1 in sample is can be seen that in 5.61mg/ -9.88mg/ grains from above-mentioned test result
Between, therefore ginseng will be defined as in finished product must not be less than 5.0mg in terms of ginsenoside Rg1;
Three, conclusion
1, pharmacodynamic action
A kind of Chinese medicine composition that treating arrhythmia cordis is formed by zhigancao decoction addition or subtraction of changes;Zhigancao decoction derives from Zhang Zhong
Scape《The Treatise on Fevrile Diseases》, " typhoid fever, intermittent pulse severe palpilation, zhigancao decoction master it " primary efficacy be benefiting qi and nourishing yin, activate yang multiple arteries and veins;It is a kind of
The Chinese medicine composition for treating arrhythmia cordis is by eight taste such as Radix Rehmanniae, ginseng, Radix Astragali, Radix Ophiopogonis, Radix Glycyrrhizae, spina date seed, Radix Salviae Miltiorrhizae, safflower
Medicine forms;Research through modern pharmacology, a kind of Chinese medicine composition that treating arrhythmia cordis have good antiarrhythmic work
With;Honey-fried licorice root:Effect is invigorating middle warmer and replenishing QI, and relieving spasm to stop pain moistens the lung and relieve the cough, purging intense heat and detonicating, mediation property of medicine;It is sweet in flavor mild-natured, returns spleen,
Stomach, the heart, lung channel;Gas and property are slow, and can rise can drop;Modern medicine study, honey-fried licorice root have apparent antiarrhythmic effect, sugared skin
Matter hormone-like effect, anti-oxidant and anti-aging effects;Radix Rehmanniae:Effect is nourishing Yin and clearing heat, and cool blood is enriched blood.It is sweet in flavor, bitter, it is slightly cold, returns
The heart, liver, stomach, the thick drop of matter are let out;Myocardial blood flow amount, reducing heart rate can be increased, and there is certain antihypertensive effect;It is yellow
Stilbene:Function be it is raw with can invigorating qi for consolidating superficies, inducing diuresis for removing edema;Toast with can tonifying middle-Jiao and Qi, control all laboured breathing syndrome of blood deficiency;Nature and flavor, it is sweet, it is micro-
Temperature enters lung, the spleen channel;It can significantly improve heart discharge, cardiac index, the often amount of fighting and index of often fighting;Ginseng:It can reinforce vital energy,
Calm the nerves, internal lesion caused by overexertion it is deficient, deficiency of food, the card of all qi and blood sperm deficiencies such as burnout;Nature and flavor:It is sweet, slight bitter, temperature;Enter spleen, lung channel;Energy
Enhance myocardial contractive power, increase cardiac output, there is cardiac effect;Increase coronary blood flow, reducing heart rate, resist myocardial ischemia work
With anti anoxia and protection cardiac muscle reduce myocardial oxygen consumption, reduce affinity of the hemoglobin to oxygen, more to tissue release
Oxygen;Radix Ophiopogonis:Effect is nourishing Yin and moistening lung, beneficial stomach production of sperm, relieving restlessness that clears away heart-fire;Nature and flavor are sweet, slight bitter, cold nature, return lung, stomach, the heart channel of Hang-Shaoyin;It improves
Myocardial contractive power and cardiac pumping function improve tolerance of the mouse ischemic myocardium to bottom oxygen, improve cardiac muscle cell's nutrition, blood flow
Amount, anti-oxidant, antifatigue effect promote liquid immune;Thus a kind of Chinese medicine composition for treating arrhythmia cordis is clinically
Play the role for the treatment of arrhythmia cordis well;
2, detection method result
This test result establishes a kind of quality determining method of Chinese medicine composition that treating arrhythmia cordis, and ginseng is one kind
The main ingredient of the Chinese medicine composition of arrhythmia cordis, ginsenoside Rg1 containing active ingredient are treated, and content is higher, as in said preparation
Main component, content directly influences therapeutic effect, therefore uses high performance liquid chromatography, using it as the finger of assay
Ingredient is marked, can reflect the quality of said preparation, a kind of Chinese medicine composition that treating arrhythmia cordis is made with the content of ginsenoside Rg1
It is reasonable for the index of quality control;Simultaneously using according to thin-layered chromatography, to spina date seed in preparation, Radix Salviae Miltiorrhizae, Radix Astragali is determined
Property differentiate, as a result on position corresponding with reference substance chromatography, show same color spot, method favorable reproducibility;The quality is examined
The foundation of survey method is for reducing preparation differences between batches, ensureing the quality of the pharmaceutical preparations, ensure that clinical efficacy is of great significance, and method
Easy to operate, accurate, reproducible, specificity is strong, can be used for controlling the quality of Dingxin capsule.
A kind of Chinese medicine composition that treating arrhythmia cordis and drug quality differentiate the clinical experiment report of detection method:
1, clinical experiment report one
(1) pharmaceutical formulation that clinical test uses
Honey-fried licorice root 35g, Radix Rehmanniae 30g, ginseng 25g, Radix Astragali 25g, Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 30g.
(2) clinical experimental study method:Selection of clinical ventricular late potential exception and TCM Syndrome Type category deficiency of both qi and yin syndrome of blood stasis
Person 30, wherein male 21, women 9;The oldest person 64 years old, reckling 42 years old are 56 years old average;Course of disease longest 3 months,
It is most 2 weeks short;Protopathy is coronary heart disease 9, outmoded 18 Myocardial Infarction Cases, cardiomyopathy 3, companion's cardiac insufficiency person 8.All diseases
Example has different degrees of ventricular premature beat, wherein 3 with atrial fibrillation.All cases while treating underlying diseases, are given
Give Chinese medicine treatment.Daily 1 dose, decocting divides 3 times and takes orally, and 1 month as a treatment course.Curative effect determinate standard:Ventricular late potential feminine gender is
It cures, it is effective that above-mentioned diagnostic criteria, which improves 1/2ms, and it is invalid not change into.Statistical is carried out using 14.0 software packages of SPSS
Analysis.As a result as follows:
11 clinical experimental study result of table
Chinese medicine fixed core square group | Ventricular late potential | Diagnostic criteria | Diagnostic criteria | Total effective rate |
It is negative | Improve 1/2ms | Without improvement | ||
30 | 19 | 5 | 6 | 79.9% |
Curative effect rate % | 63.3 | 16.6 | 20.1 |
(3) clinical test results:
Show that fixed core square improves and the overall efficiency of recovery ventricular late potential is up to 79.9% by clinical observation, faces
Bed curative effect is affirmed, to provide new idea and method extremely for treatment ventricular late potential.
2, clinical experiment report two
(1) pharmaceutical formulation that clinical test uses
Honey-fried licorice root 35g, Radix Rehmanniae 30g, ginseng 20g, Radix Astragali 25g, Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 40g, safflower 20g, spina date seed 40g.
(2) clinical experimental study method:Selection of clinical is clarified a diagnosis as by protopathy, coronary heart disease, high worry, the wind heart
The atrial fibrillation that disease, myocarditis, cardiomyopathy, pulmonary heart disease cause, and TCM Syndrome Type category deficiency of both qi and yin syndrome of blood stasis person, totally 60.Its
Middle male 28, women 32;Oldest 75 years old, minimum 29 years old.The course of disease is all at 1 year or more;Protopathy, coronary heart disease
13, high worry 10, rheumatic heart disease 10, myocarditis 9, cardiomyopathy 8, pulmonary heart disease 5, unknown 5 of reason.All diseases
Example while treating underlying diseases, gives Chinese medicine treatment.One dose per day takes orally in three times, and 30 doses as a treatment course, generally
A course for the treatment of is taken, single cases can take two courses for the treatment of according to my situation.We are just included in statistics after one course for the treatment of
Object, observe Chinese medicine the effect of situation.All antiarrhythmic drugs are deactivated during taking Chinese medicine.With the disease of observation post administration patient
Shape improves situation.Curative effect determinate standard:(1) effective:Atrial attack number reduces 50%, and ventricular rate slows down 1/3, and symptom is apparent
Improvement is effective.(2) effectively:Atrial attack number significantly reduces, and ventricular rate part slows down, and it is to have that symptom part, which improves,
Effect.(3) invalid:Atrial attack number does not change, and it is invalid that symptom, which does not improve,.
12 clinical experimental study result of table
Chinese medicine fixed core square group | It is effective | Effectively | In vain | It is efficient |
30 | 19 | 32 | 9 | 85% |
Cardinal symptom | Palpitaition, shortness of breath uncomfortable in chest | Insomnia, dreaminess | Dizzy, burnout | Tongue vein improves |
Symptom improvement rate % | 85 | 60 | 55 | 46 |
(3) clinical test results:
Clinical observation shows atrial fibrillation deficiency of both qi and yin and syndrome of blood stasis on the basis of conventional therapy plus in invigorating Qi
Medicine can significantly improve the clinical efficacy of patient, improve the quality of life of patient.
Claims (14)
1. a kind of Chinese medicine composition for treating arrhythmia cordis, including Chinese medicine major ingredient and pharmaceutic adjuvant, it is characterised in that:In described
Medicine major ingredient is made of following ingredients weight parts proportioning Chinese medicine:Honey-fried licorice root 25-40g, Radix Rehmanniae 25-30g, ginseng 20-25g, Radix Astragali
25-40g, Radix Ophiopogonis 25-40g, Radix Salviae Miltiorrhizae 35-40g, safflower 20-25g, spina date seed 20-40g.
2. a kind of Chinese medicine composition for treating arrhythmia cordis according to claim 1, it is characterised in that:The Chinese medicine master
Material is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 30g, Radix Rehmanniae 25g, ginseng 20g, Radix Astragali 30g, Radix Ophiopogonis
25g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 20g.
3. a kind of Chinese medicine composition for treating arrhythmia cordis according to claim 1, it is characterised in that:The Chinese medicine master
Material is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 30g, Radix Rehmanniae 25g, ginseng 25g, Radix Astragali 25g, Radix Ophiopogonis
25g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 25g.
4. a kind of Chinese medicine composition for treating arrhythmia cordis according to claim 1, it is characterised in that:The Chinese medicine master
Material is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 25g, Radix Rehmanniae 30g, ginseng 20g, Radix Astragali 35g, Radix Ophiopogonis
30g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 20g.
5. a kind of Chinese medicine composition for treating arrhythmia cordis according to claim 1, it is characterised in that:The Chinese medicine master
Material is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 25g, Radix Rehmanniae 25g, ginseng 20g, Radix Astragali 30g, Radix Ophiopogonis
30g, Radix Salviae Miltiorrhizae 40g, safflower 20g, spina date seed 25g.
6. a kind of Chinese medicine composition for treating arrhythmia cordis according to claim 1, it is characterised in that:The Chinese medicine master
Material is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 30g, Radix Rehmanniae 25g, ginseng 20g, Radix Astragali 30g, Radix Ophiopogonis
30g, Radix Salviae Miltiorrhizae 35g, safflower 25g, spina date seed 25g.
7. a kind of Chinese medicine composition for treating arrhythmia cordis according to claim 1, it is characterised in that:The Chinese medicine master
Material is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 40g, Radix Rehmanniae 25g, ginseng 25g, Radix Astragali 30g, Radix Ophiopogonis
25g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 25g.
8. a kind of Chinese medicine composition for treating arrhythmia cordis according to claim 1, it is characterised in that:The Chinese medicine master
Material is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 25g, Radix Rehmanniae 25g, ginseng 20g, Radix Astragali 30g, Radix Ophiopogonis
30g, Radix Salviae Miltiorrhizae 35g, safflower 25g, spina date seed 40g.
9. a kind of Chinese medicine composition for treating arrhythmia cordis according to claim 1, it is characterised in that:The Chinese medicine master
Material is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 35g, Radix Rehmanniae 30g, ginseng 25g, Radix Astragali 25g, Radix Ophiopogonis
30g, Radix Salviae Miltiorrhizae 35g, safflower 20g, spina date seed 30g.
10. a kind of Chinese medicine composition for treating arrhythmia cordis according to claim 1, it is characterised in that:The Chinese medicine
Major ingredient is made of following ingredients weight parts optimum ratio Chinese medicine:Honey-fried licorice root 35g, Radix Rehmanniae 30g, ginseng 20g, Radix Astragali 25g, Radix Ophiopogonis
25g, Radix Salviae Miltiorrhizae 40g, safflower 20g, spina date seed 40g.
11. a kind of Chinese medicine composition for treating arrhythmia cordis according to claim 1, it is characterised in that:Described is medicinal
Auxiliary material is one or more of in dextrin, starch, lactose.
12. a kind of preparation method of Chinese medicine composition for treating arrhythmia cordis according to claim 1, it is characterised in that:
A kind of preparation method of Chinese medicine composition for treating arrhythmia cordis includes the following steps:
(1) honey-fried licorice root, Radix Rehmanniae, ginseng, Radix Astragali are taken in prescription ratio, 70% ethyl alcohol measured with 10 times, heating and refluxing extraction two
Secondary, 2 hours every time, filtering, filtrate merged, and recycling ethyl alcohol obtains liquid I;
(2) Radix Ophiopogonis, Radix Salviae Miltiorrhizae, safflower, spina date seed are taken in prescription ratio, impregnated 30 minutes, the gained dregs of a decoction in step (1) are added,
Common decocting 2 times, 12 times of water, decoct 2 hours for the first time, and filtration obtains liquid II, and second of 8 times of water decocts 1.5 hours, filter
It crosses, obtains liquid III, collect distillate twice, obtain liquid IV;
(3) liquid I, II, III, IV is merged, mixing carries out coarse filtration and refined filtration, refined filtration liquid Three-effect energy-saving with plate and frame filter press
It is 1.15 that inspissator, which is concentrated into relative density, temperature 60 C;Concentrate spray drying process, 6000 ml/min of feed speed,
6000 revs/min of centrifugal speed, 120 DEG C of inlet air temperature, prepares extract powder;20% dextrin mixing is added in cream powder, with 80% second
Alcohol wetting granulation, wet granular boiled bed drying, 75 DEG C of wind-warm syndrome;Beta-cyclo dextrin included compound powder, whole grain is added;Inspection is sub-packed in aluminium
It moulds in bag film, often wraps 3 grams, both obtain finished dosage form.
13. a kind of preparation method of Chinese medicine composition for treating arrhythmia cordis according to claim 1 or 12, feature exist
In:Preparation in the step (3) is pill, capsule, decoction, powder, electuary, particle or oral solution.
14. a kind of quality determining method of Chinese medicine composition for treating arrhythmia cordis according to claim 1, feature exist
In:A kind of quality determining method of Chinese medicine composition for treating arrhythmia cordis is as follows:
One, instrument and reagent
LC-10P liquid phase pump LC-10UV UV detector, big Liaanjiang county Shen separation science Technology Co., Ltd. production;Chromatographic column 1
(Hypersil):Dalian Yi Lite Co., Ltds provide;5 μ, 4.6mm × 200mm;Chromatographic column 2 (Spherigel):Big Liaanjiang county Shen
Separation science Co., Ltd provides;5 μ, 4.6mm × 200mm;Agents useful for same acetonitrile is chromatographically pure, the limited public affairs of Shandong king's Yu industry
Take charge of Yucheng chemical plant;Water is double distilled water, and other reagents are that analysis is pure;Ginsenoside Rg1's reference substance, Chinese pharmaceutical biological product
Calibrating is provided, and assay is used, lot number 0703-9812;
Two, method and result
1, thin layer differentiates
(1) thin layer of Radix Salviae Miltiorrhizae differentiates
This product content 2g is taken, water 50ml, ultrasonic extraction 30 minutes is added to let cool, centrifuges, takes supernatant, PH is adjusted with dilute hydrochloric acid
Value is 1-2, is extracted 2 times, each 20ml with ethyl acetate, merges ethyl acetate liquid, is evaporated, and residue adds methanol 1ml to make dissolving, is made
For test solution;Protocatechualdehyde reference substance separately is taken, adds methanol that solution of every 1ml containing 1mg is made, as a contrast product solution;According to
Thin-layered chromatography is tested, and with reference to Chinese Pharmacopoeia one annex VIB of version in 2000, draws 5 μ l of reference substance solution, test solution
10-20 μ l are put on the silica gel g thin-layer plate in same using 0.4% sodium carboxymethylcellulose as binder, respectively with chloroform-acetone-
Formic acid is solvent, chloroform:Acetone:The ratio of formic acid is 8:1:1, it is unfolded, takes out, dry, spray is molten with 5% ferric trichloride ethyl alcohol
Liquid, it is clear that hot wind is blown to spot development, sets and is inspected under daylight;In test sample chromatography, on position corresponding with reference substance chromatography,
The spot of aobvious same color;
(2) thin layer of Radix Astragali differentiates
This product content 3g is taken, methanol 30ml is added, is ultrasonically treated 30 minutes, lets cool, is filtered, filtrate is evaporated, and residue adds water 20ml
Make dissolving, be transferred in separatory funnel, adds water saturated n-butanol shaking extraction 2 times, be followed successively by 30ml, 20ml, merge positive fourth
Alcohol extract is washed 2 times, each 20ml with 1% sodium hydroxide solution, discards lye, then the water washing 2 being saturated with n-butanol
Secondary, each 15ml discards aqueous, and n-butanol liquid is evaporated, and residue adds methanol 1-2ml to make dissolving, as test solution;Separately take Huang
Stilbene first glycosides reference substance, adds methanol that solution of every 1ml containing 0.5mg is made, as a contrast product solution;It is tested according to thin-layered chromatography, ginseng
According to one VI B of annex of China's coastal port, each 5 μ l of above two solution are drawn, are put respectively in same silica gel g thin-layer plate
On, using 10 DEG C of overnight lower layer's solution arranged below of chlorofonn-ethylacetate-methanol-water as solvent, chloroform:Ethyl acetate:First
Alcohol:The ratio of water is 15: 40: 22: 10, is unfolded, and takes out, dries, and sprays with 10% ethanol solution of sulfuric acid, spot is heated at 105 DEG C
Point colour developing is clear;In test sample chromatography, on position corresponding with reference substance chromatography, the spot of same color is shown;
(3) thin layer of spina date seed differentiates
This product content 4g is taken, water 50ml, ultrasonic extraction 30 minutes is added to let cool, centrifuges, supernatant is taken, with water saturated positive fourth
Three times, each 25ml merges n-butanol liquid, is extracted 2 times, each 50ml with ammonia solution, discards ammonia solution, n-butanol liquid for alcohol extracting
It is extracted 2 times, each 30ml with distilled water, discards aqueous solution, n-butanol liquid is evaporated, and residue adds methanol 1ml to make dissolving, as examination
Product solution;Saponin A reference substance separately is taken, adds methanol that solution of every 1ml containing 1mg is made, as a contrast product solution.According to thin layer
Chromatography experiment draws each 5-10 μ l of above two solution with reference to Chinese Pharmacopoeia version one, annex VIB in 2000, put respectively in
On same silica gel g thin-layer plate, using 10 DEG C of lower layer's solution arranged below of chloroform-methanol-water as solvent, chloroform:Methanol:Water
Ratio is 65:35:10, it is unfolded, takes out, dry, sprays with 1% vanillic aldehyde concentrated sulfuric acid solution, it is clear that hot wind is blown to spot development, sets
It is inspected under daylight;In test sample chromatography, on the corresponding position of product chromatography, the spot of same color 1 is shown;
2, assay
(1) chromatographic condition:
Chromatographic column 1 (Hypersil):5 μ, 4.6mm × 200mm;Chromatographic column 2 (Spherigel):5 μ, 4.6mm × 200mm;With ten
Eight alkyl silane bonded silica gels are filler;- 0.05% phosphoric acid of acetonitrile is mobile phase;Acetonitrile:The ratio of 0.05% phosphoric acid is 20:
80, Detection wavelength 203nm;
(2) preparation of reference substance solution:
Precision weighs ginsenoside Rg1 reference substance 10.78mg, is placed in 10ml volumetric flasks, and methanol is added to make it dissolve in right amount and dilute
It releases to scale, product solution as a contrast after shaking up;Precision draws above-mentioned reference substance solution 2.5ml, is placed in 5ml volumetric flasks, adds
Methanol dilution is to scale, product dilute solution as a contrast after shaking up, a concentration of 0.539mg/ml of dilute solution;
(3) preparation of test solution:
The a small amount of content of this product is taken, it is finely ground, take 2g, accurately weighed and water-saturated n-butanol 50ml is added, weighed weight, surpasses again
Sound extracts 30 minutes, stands overnight, and twice ultrasonic extracts 30 minutes, and weighed weight supplies the weight of less loss with water-saturated n-butanol
Amount, filtration discard primary filtrate, collect subsequent filtrate;Precision draws subsequent filtrate 25ml, sets in separatory funnel, with 0.5% hydroxide
Sodium water solution washs 2 times, each 10ml, merges butanol solution, and the water 15ml being saturated with n-butanol is washed 1 time, discards washing
Liquid, butanol solution water bath method;Residue adds methanol to make to be dissolved in 25ml measuring bottles, adds methanol dilution to scale, shakes up, use is micro-
Hole filter membrane filters to obtain the final product, empty a diameter of 0.45 μm of the net of miillpore filter;
(4) selection of Detection wavelength:
Ginsenoside Rg1's reference substance solution 50 μ l, solution concentration 1.078mg/ml are taken, methanol about 5ml is added, with Shimadzu UV-260
It is scanned in 400-200nm wave-length coverages, UV absorption figure is shown in Fig. 1, can be seen that ginsenoside Rg1 from UV absorption Fig. 1
There is absorption peak in 203nm;Therefore select 203nm for ginsenoside Rg1's assay wavelength;
(5) ginsenoside Rg1's reference substance linear relationship is investigated:
Accurate 2 μ l of ginsenoside Rg1's reference substance dilute solution, 4 μ l, 6 μ l, 8 μ l and 10 μ l, the solution concentration drawn is respectively
1.078mg/ml is injected separately into liquid chromatograph, measures ginsenoside Rg1's chromatographic peak peak area, sample size and peak area
Relationship is shown in Table 1;
1 ginsenoside Rg1's reference substance sample size of table and peak area relationship
Calibration curve equation is Y=9.163 × 10-8X+1.074×10-2R=0.9997;
Sample introduction is ranging from:2.156 μ of μ g~10.078 g;
(5) ginsenoside Rg1's reference substance linear relationship is investigated:
Accurate 2 μ l of ginsenoside Rg1's reference substance dilute solution, 4 μ l, 6 μ l, 8 μ l and 10 μ l, the solution concentration drawn is respectively
1.078mg/ml is injected separately into liquid chromatograph, measures ginsenoside Rg1's chromatographic peak peak area, sample size and peak area
Relationship is shown in Table 1;
1 ginsenoside Rg1's reference substance sample size of table and peak area relationship
Calibration curve equation is Y=9.163 × 10-8X+1.074×10-2R=0.9997;
Sample introduction is ranging from:2.156 μ of μ g~10.078 g;
(6) precision test:
20,090801 sample of lot number is taken, it is finely ground, 2g is taken, it is accurately weighed, it is tried by test liquid preparation method under " assay " item
It tests, precision draws 5 μ l of test liquid, amounts to 5 parts, is injected separately into liquid chromatograph, measures ginsenoside Rg1's peak area and is respectively
20254816,20722368,19968224,20929208,20274486, relative standard deviation 1.90%;
(7) blank test:
Recipe quantity medicinal material is taken, ginseng is removed, negative controls are made by preparation process, then by being tested under " assay " item, make
The negative controls solution of standby scarce ginseng crude drug;By negative controls solution, test solution and each 5 μ l of reference substance solution, divide
Zhu Ru not be in liquid chromatograph, measurement result shows that negative fluid has no corresponding miscellaneous at ginsenoside Rg1's chromatographic peak retention time
Mass peak interferes;
(8) stability test:
20,090801 sample of lot number is taken, it is finely ground, 2g is taken, it is accurately weighed, it is tried by test liquid preparation method under " assay " item
It tests, when test liquid is placed 0,4,8 and 12 hour, draws test liquid and each 5 μ l of ginsenoside Rg1's reference substance solution, point
Zhu Ru not be in liquid chromatograph, it is respectively 20254816,20557692,20527968,20977204 to measure peak area, opposite to mark
Quasi- deviation is 1.45%;From test result it is found that test liquid is placed 12 hours, Determination of Content of Ginsenoside Rg_1 is basicly stable.From above-mentioned
As a result it is found that this assay method, test solution precision are good;
(9) reappearance test:
20,090801 sample of lot number is taken, it is finely ground, 2g is taken, it is accurately weighed, it is tried by test liquid preparation method under " assay " item
It tests, Determination of Content of Ginsenoside Rg_1 in determination sample, result is:8.86,8.98,9.08,9.02,8.80mg/, average content is
8.94mg/, relative standard deviation 1.29%;From test result it is found that Determination of Content of Ginsenoside Rg_1 measures reappearance test symbol
Close regulation;
(10) sample recovery rate is tested:
20,090801 sample of lot number is taken, it is finely ground, 1g is taken, it is accurately weighed, it is tried by test liquid preparation method under " assay " item
It tests, amounts to 5 parts, it is accurate respectively that ginsenoside Rg1 reference substance 17mg is added, by being tested under " assay " item, measure mark-on sample
Determination of Content of Ginsenoside Rg_1 in product calculates, obtains the rate of recovery of this content assaying method ginsenoside Rg1;Its test result is shown in Table
2;
2 Determination of Content of Ginsenoside Rg_1 of table measures recovery test result
From above-mentioned recovery test result it is found that this method rate of recovery is good;
(11) Determination of Content of Ginsenoside Rg_1 measures in sample:
Each 20 of the sample of different lot numbers is taken, it is finely ground, 2g is taken, it is accurately weighed, by method test under " assay " item, measure people
Join saponin(e Rg1 contents, calculates, the result is shown in tables 3;
Determination of Content of Ginsenoside Rg_1 measurement result in 3 sample of table amounts to 10 batches
Determination of Content of Ginsenoside Rg_1 is can be seen that in sample between 5.61mg/ -9.88mg/ from above-mentioned test result, because
This will be defined as ginseng in finished product must not be less than 5.0mg in terms of ginsenoside Rg1;
Three, conclusion
1, pharmacodynamic action
A kind of Chinese medicine composition that treating arrhythmia cordis is formed by zhigancao decoction addition or subtraction of changes;Zhigancao decoction is from Zhang Zhongjing
《The Treatise on Fevrile Diseases》, " typhoid fever, intermittent pulse severe palpilation, zhigancao decoction master it " primary efficacy be benefiting qi and nourishing yin, activate yang multiple arteries and veins;A kind for the treatment of
The Chinese medicine composition of arrhythmia cordis is by the eight taste Chinese medicine group such as Radix Rehmanniae, ginseng, Radix Astragali, Radix Ophiopogonis, Radix Glycyrrhizae, spina date seed, Radix Salviae Miltiorrhizae, safflower
At;Research through modern pharmacology, a kind of Chinese medicine composition that treating arrhythmia cordis have good antiarrhythmic effect;Toast
Radix Glycyrrhizae:Effect is invigorating middle warmer and replenishing QI, and relieving spasm to stop pain moistens the lung and relieve the cough, purging intense heat and detonicating, mediation property of medicine;It is sweet in flavor mild-natured, returns spleen, stomach, the heart,
Lung channel;Gas and property are slow, and can rise can drop;Modern medicine study, honey-fried licorice root have apparent antiarrhythmic effect, glucocorticoid
Sample acts on, anti-oxidant and anti-aging effects;Radix Rehmanniae:Effect is nourishing Yin and clearing heat, and cool blood is enriched blood.It is sweet in flavor, bitter, be slightly cold, the thoughts of returning home, liver,
Stomach, the thick drop of matter are let out;Myocardial blood flow amount, reducing heart rate can be increased, and there is certain antihypertensive effect;Radix Astragali:Work(
Be it is raw with can invigorating qi for consolidating superficies, inducing diuresis for removing edema;Toast with can tonifying middle-Jiao and Qi, control all laboured breathing syndrome of blood deficiency;Nature and flavor, sweet, tepor enters
Lung, the spleen channel;It can significantly improve heart discharge, cardiac index, the often amount of fighting and index of often fighting;Ginseng:It can reinforce vital energy, calm the nerves,
Internal lesion caused by overexertion it is deficient, deficiency of food, the card of all qi and blood sperm deficiencies such as burnout;Nature and flavor:It is sweet, slight bitter, temperature;Enter spleen, lung channel;The heart can be enhanced
Myotility increases cardiac output, has cardiac effect;Increase coronary blood flow, reducing heart rate, function of resisting myocardial ischemia resists
Anoxic and protection cardiac muscle, reduce myocardial oxygen consumption, reduce affinity of the hemoglobin to oxygen, discharge more oxygen to tissue;Wheat
Winter:Effect is nourishing Yin and moistening lung, beneficial stomach production of sperm, relieving restlessness that clears away heart-fire;Nature and flavor are sweet, slight bitter, cold nature, return lung, stomach, the heart channel of Hang-Shaoyin;Improve cardiac muscle
Convergent force and cardiac pumping function improve tolerance of the mouse ischemic myocardium to bottom oxygen, improve cardiac muscle cell's nutrition, blood flow,
Anti-oxidant, antifatigue effect promotes liquid immune;Thus a kind of Chinese medicine composition for treating arrhythmia cordis clinically has very
The effect of good treatment arrhythmia cordis;
2, detection method result
This test result establishes a kind of quality determining method of Chinese medicine composition that treating arrhythmia cordis, and ginseng is a kind for the treatment of
The main ingredient of the Chinese medicine composition of arrhythmia cordis, ginsenoside Rg1 containing active ingredient, and content is higher, as the master in said preparation
Want ingredient, content directly influences therapeutic effect, therefore uses high performance liquid chromatography, the index using it as assay at
Point, it can reflect the quality of said preparation, a kind of Chinese medicine composition that treating arrhythmia cordis is using the content of ginsenoside Rg1 as matter
The index of amount control is reasonable;Simultaneously using according to thin-layered chromatography, to spina date seed in preparation, Radix Salviae Miltiorrhizae, Radix Astragali has carried out qualitative mirror
Not, as a result on position corresponding with reference substance chromatography, the spot of same color, method favorable reproducibility are shown;The quality testing side
The foundation of method is for reducing preparation differences between batches, ensureing the quality of the pharmaceutical preparations, ensure that clinical efficacy is of great significance, and method operates
Simply, accurate, reproducible, specificity is strong, can be used for controlling the quality of Dingxin capsule.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810675116.3A CN108478703A (en) | 2018-06-27 | 2018-06-27 | A kind of Chinese medicine composition and quality determining method for treating arrhythmia cordis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810675116.3A CN108478703A (en) | 2018-06-27 | 2018-06-27 | A kind of Chinese medicine composition and quality determining method for treating arrhythmia cordis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108478703A true CN108478703A (en) | 2018-09-04 |
Family
ID=63343301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810675116.3A Pending CN108478703A (en) | 2018-06-27 | 2018-06-27 | A kind of Chinese medicine composition and quality determining method for treating arrhythmia cordis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108478703A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101422562A (en) * | 2007-10-29 | 2009-05-06 | 辽宁中医药大学附属医院 | Medicine for treating premature beat and atrial fibrillation |
CN101637565A (en) * | 2008-07-28 | 2010-02-03 | 北京中泰天和科技有限公司 | Pure Chinese medicinal preparation for treating arrhythmia |
-
2018
- 2018-06-27 CN CN201810675116.3A patent/CN108478703A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101422562A (en) * | 2007-10-29 | 2009-05-06 | 辽宁中医药大学附属医院 | Medicine for treating premature beat and atrial fibrillation |
CN101637565A (en) * | 2008-07-28 | 2010-02-03 | 北京中泰天和科技有限公司 | Pure Chinese medicinal preparation for treating arrhythmia |
Non-Patent Citations (3)
Title |
---|
张彦等: "定心胶囊质量标准研究", 《中国中医药信息杂志》 * |
***等: "《新编常用中药有效成分手册》", 31 January 2008, 北京协和医科大学出版社 * |
王立玉等: "中医药治疗房颤研究进展 ", 《长春中医药大学学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100548323C (en) | A kind of pharmaceutical composition of making by Herb Gynostemmae Pentaphylli, Radix Panacis Quinquefolii and the Radix Astragali | |
CN106692297A (en) | Composition for assistedly decreasing blood sugar, and preparation method and application thereof | |
CN102091083B (en) | Petroleum ether extract of traditional Chinese medicine for preventing and treating glucose and lipid metabolic disturbance and preparation method thereof | |
CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
CN101496870B (en) | Chinese medicinal composition for resolving phlegm and suppressing cough as well as preparation method and quality control method thereof | |
CN101019952B (en) | Medicine for treating eczema and preparation process of its ointment | |
CN103550398B (en) | Composition for relieving fatigue as well as preparation method and medical application thereof | |
CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
CN108478703A (en) | A kind of Chinese medicine composition and quality determining method for treating arrhythmia cordis | |
CN107308317B (en) | Traditional Chinese medicine composition for preventing and treating radiation damage | |
CN102652774B (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
CN106177759B (en) | A kind of compound Chinese medicinal preparation and its preparation process for treating coronary disease and angina pectoris | |
CN115252753A (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
KR20100133079A (en) | Herbal extracts composition for the prevention of alcoholic fatty liver, hyperlipidemia and hangover | |
CN103432420A (en) | Traditional Chinese medicine composition for treating diabetes, and preparation method and detection method thereof | |
CN103908571A (en) | Compound traditional Chinese medicine preparation for treating heart disease | |
CN110507759A (en) | A kind of three yellow Chinese herbal preparation of particles and preparation method thereof with control hyperglycemia | |
CN112089830A (en) | Traditional Chinese medicine incense for relieving coronary heart disease and angina pectoris and preparation process thereof | |
CN101371877B (en) | Qi tian dropping pill extract and Qi tian dropping pill as well as method for producing the same | |
CN1899410A (en) | Medicine for treating cardiovascular disease and its preparing method and quality control method | |
CN103860877A (en) | Pharmaceutical composition for treating diabetes, and preparation method and application thereof | |
CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
CN108066494A (en) | A kind of enuresis nocturna frequency effect liquid and preparation method thereof | |
CN100355424C (en) | Extractive of 'Zong'wood for treating diabetes, and application of saponin of 'Zong' wood for treating diabetes | |
CN108041603A (en) | It is a kind of that there is health food for improving sleep effect and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180904 |